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Pharmaceutical formulation development can be a challenging task during which many, 
sometimes contradicting factors need to be considered such as the formulation composition, 
suitability of excipients for each manufacturing step, or scalability of the process(es) applied. 
Development of dry powder formulations for inhalation can be especially challenging as only 
particles of very narrow aerodynamic particle size can enter the lungs while they are in fact 
designed by nature to prevent entry of foreign material. Additionally, there are mechanisms in 
place that quickly remove any particles that do enter them. Formulations with micronised drug 
substance particles are mostly being used to bypass the anatomical obstacles but the drug’s 
deposition efficiency is commonly rather low. Utilisation of particle engineering, which leverages 
on favourable particle properties being tailored through a manufacturing process, offers a 
possibility to address these anatomical and performance challenges; however, their 
manufacturing is often linked to usage of organic solvents. A formulation scientist also needs to 
keep in mind that for any kind of formulation, drug dissolution is the key prerequisite for 
bioavailability and thus also for the drug’s action. This can be a challenging step especially for a 
poorly water–soluble drug depending on its solubilities in the respective biological fluids as these 
are made up of water most of the time. Due to the obstacles inhaled drug particles encounter on 
their way to dissolved state, the drug needs to dissolve before it is cleared by the body’s defence 
mechanisms to effectively work. Thus, study of the dissolution kinetics of solid formulations is of 
considerable interest. Unlike for orally delivered drug substance, no fully established 
pharmacopoeial dissolution method for inhaled medicines exists, likely due to the complexity to 
mimic reasonably well the in vivo situation. 
The objective of this work was to combine industry-viable manufacturing processes to engineer 
inhalation powders of superior pharmaceutical performance and prolonged lung residence time 
thanks to favourable physical-chemical properties, and to study dissolution behaviour and 
biological fate of these powders using a dissolution vessel and in vitro cell culture system, 
respectively. The work intentionally used industrially established processes and only water as a 
solvent to offer the possibility to ultimately introduce this as platform technology for pulmonary 
formulation development allowing optimised inhalation drug product performance. 
High-energy wet media milling was used for production of nanoparticles of a poorly-water 
soluble model drug (budesonide). The nanosuspension was stabilised using D-α-tocopherol 
polyethylene glycol 1000 succinate, which allowed to create nanosuspension of ≈ 260 nm median 
particle size at specific energy input of ≈ 137 MJ/kg. Subsequently used particle engineering via 
spray drying aimed to create composite particles of maximal fine particle fraction for deep lung 
deposition, maximal geometric size, minimal density, and fast dissolution. Spray drying at high 
Peclet numbers was crucial to successfully achieve this goal and it guided the choice of 
formulation composition and process parameters. Among the tested additives were leucine, 
trileucine, mannitol, albumin, glycine, and a pore former ammonium carbonate. Different spray 
drying temperatures and atomising pressures, as well as feedstock concentration, were screened 




formulation, prepared with the nanoparticulate drug together with leucine and ammonium 
carbonate, exhibited a high fine particle fraction of 61% as assessed by the next generation 
impactor deposition and had a median particle size of ≈ 4.4 µm. The deposition efficiency 
correlated well also with the bulk and effective density measurements for which this formulation 
had lowest and second lowest values, respectively. The aerodynamic performance was well above 
the commercial, carrier-based product, which reached only 21% of fine particle fraction. 
Interestingly, when the micronised drug was not processed by wet media milling, even with the 
use of same additives and process conditions, only 22% of fine particle fraction could be reached. 
This suggested that the wet media milling step was indispensable for improved aerodynamic 
performance and that only the combination of the processes allowed to harness the advantages 
of both. Moreover, the geometric size of the composite spray-dried particles was larger than that 
of the micronised drug, offering additionally the potential to evade phagocytosis for a longer time 
period compared to the micronized drug as this is a size-driven process. 
Within the first part of the work, five formulations of comparable geometric particle size, but 
different densities and particle shapes were studied in depth to assess their dissolution 
behaviour. For this purpose, a USP2 paddle apparatus was modified with the aim to mimic closely 
the in vivo conditions in terms of liquid hydrodynamics and volumes. For the modification, an 
insert from impactor stage, on which aerodynamically classified particles were deposited, was 
placed into the dissolution vessel; the setup thus resembled a USP5 (paddle-over-disk) apparatus. 
Using such setup, the dissolution behaviour of powders from three different stages was studied 
as a function of particle properties such as aerodynamic particle size, shape, or specific surface 
area. A permeable polycarbonate membrane was fixed onto each insert, which enabled the 
creation of an inner and outer compartment of different volumes. In the inner compartment, 
between the membrane and the insert surface, a small liquid amount of 200 µL was in direct 
contact with the powders and allowed dissolution in small, unstirred liquid volume. In the outer 
compartment was 300 mL of the stirred dissolution media into which the drug permeated upon 
its dissolution in the inner compartment. Dissolution of all aerodynamically classified fractions 
showed a very fast onset and was largely completed within 30 minutes irrespective of the 
formulation and the impactor stage. To further analyse this observation, mathematical kinetic 
modelling was used to deduce the drug’s dissolution rate coefficients in each formulation in all 
three stages. From this it was found that the dissolution rate was determined by the properties 
of the drug nanoparticles, mainly particle size, rather than by the variable properties of the 
composite microparticles., This then explained why no differences among the formulations and 
stages were observed when same drug nanoparticles were used in the formulations. 
Second part of the work aimed to investigate these aerodynamically classified composite 
powders even further using an in vitro cell culture system, which should have provided more 
representative in vivo conditions compared to the dissolution vessel. For this purpose, the next 
generation impactor was successfully modified for the first time to allow deposition on an A549 
cell culture, cultivated on a low-profile, Matrigel®-coated cell culture insert. These alveolar type 
II cells were grown at an air-liquid interface, which allowed formation of a surfactant layer similar 
to the one present in the alveolar lung region. It was again of interest to evaluate whether particle 
properties like shape, density, or size affect the dissolution behaviour in this miniaturised setup. 
In this setup, it was assumed that the drug dissolution starts immediately upon particle 
deposition and any dissolved solute is translocated into the intracellular compartment, where it 




in the basal solution was determined for four to eight hours upon deposition, while its amount on 
the cell surface and in the interior of the cell monolayer was evaluated at the end of the 
experiments. Any induced cell damage was assessed also at the end of the experiment by 
measurement of the lactate dehydrogenase leakage from the cell membrane. Significant 
differences in the total deposited drug amount and the amount remaining on the cell surface at 
the end of the experiment were found between different formulations and impactor stages. The 
deposited amount negatively affected the dissolution of the drug as it took rather long (≥ 4 hours) 
for larger powder amounts to dissolve despite the drug’s nano-range size. In fact, the dissolution 
took considerably longer than in the dissolution vessel setup, implying potential negative impact 
on local bioavailability as alveolar phagocytic clearance has similar half-life. Prolonged time 
required for complete drug dissolution and cell uptake in case of the large deposited powder 
amounts also suggested initial drug saturation of the surfactant layer. Interestingly, irrespective 
of the stage or formulation, roughly half of the deposited drug amount was taken up by the cells 
and metabolised to a large extent to its metabolic conjugate with oleic acid. Additionally, kinetic 
modelling was performed to evaluate the kinetics of drug dissolution and its uptake into the cells, 
metabolism into the oleate metabolite, and release into the basal solution, and supported the 
conclusions made based on the experimental results. However, it is important to note that partial 
cell damage was observed, which was possibly caused by the impaction of particles on the cells. 
This clearly indicated the need to further improve the experimental setup to reduce the cells 
membrane damage. 
This work provided many insights into dry powder for inhalation formulation development and 
in vitro testing of inhalation powders. It focused on formulation composition and process 
optimisation and use of industrially established, solely water-based processes. This potentially 
allows establishment of the presented approach as a platform technology. It clearly showed that 
when formulating inhalation powders using this platform, equal importance needs to be given to 
drug pre-processing by particle size reduction as to spray drying if advantageous aerodynamic 
performance over carrier-based formulations should be achieved. It also showed that large 
particles of low density and enhanced aerodynamic performance, which could be used for 
targeted drug delivery, can be engineered using only water-based processes. Thorough in vitro 
testing using two different drug dissolution configurations showed the clear need to consider the 
test’s purpose to select a relevant setup. For predicting local bioavailability, the newly developed 
cell culture in vitro system was able to provide useful insights into the process and kinetics of 
drug dissolution and cell uptake following powder deposition on an alveolar cell surface and it 
further highlighted the importance of fluid volume for formulation properties’ study. As stage-
specific drug distribution in different cell compartments and drug’s amount in each compartment 
are relevant for local bioavailability and therapeutic effect, this setup offers more possibilities for 
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It is not an overstatement to claim that pulmonary drug delivery is one of its kind. First appearing 
in ≈ 1500 BC, inhalation of vaporized remedies such as from henbane leaves was mostly applied 
to treat breathlessness and noisy breathing. Asthma and consumption (nowadays called 
tuberculosis) had been the most common diseases afflicting the mankind since centuries though 
they have been treated in earnest only for less than a hundred years. It was the usage of inhaled 
anaesthetics during the 19th century that considerably popularised this delivery route. [1] It is 
unique in the sense that lungs are by their nature designed to not allow any foreign particles to 
enter or in the case that happens, to remove the xenobiotics quickly by various removal 
mechanisms. By intentionally bringing drugs to the lungs, we are therefore trying to circumvent 
the natural processes. Yet, lungs present a very attractive delivery route: it is a logical choice for 
local treatment of the pulmonary tree diseases, while for the systemic treatment lungs offer 
several advantages such as a very large absorption area, thin air-blood barrier, high blood 
perfusion, or avoidance of first-pass effect. [2] 
First inhalation therapies using a kind of a device were based on inhalation of volatile substances 
in form of vapours, while solid substances were indirectly inhaled using pipes or by smoking 
cigarettes. Later on, also pressurized systems and devices for direct dry powder inhalation 
started to be used, though they have seen an advent only during the 20th century. [2] However, 
already in the 19th century it has been noticed that large droplets do not help the deep lungs, 
setting the first basis for particle-size dependant treatment [1]. This has been made more 
accurate in the 1970s by visualising regional deposition of radiolabelled materials, which showed 
that particles of aerodynamic particle size of 5 µm and smaller, ideally in the 1 – 5 µm range, can 
effectively reach the pulmonary structures [3]. 
In fact, it is the aerodynamic behaviour of a particle in an air stream that is one of the main aspects 
guiding the particle’s deposition. In line with this, the diameters for consideration and any 
comparison are the aerodynamic ones. As explained in detail in chapter 2.1.2.1, this diameter is 
proportional to particle’s geometric particle size and square root of particle density, and inversely 
proportional to square root of particle shape factor. All these properties, together with inhalation 
flow rate, device specifics, and lung anatomy, determine how long upon inhalation will a particle 
follow the air streamlines, passing through bifurcating airways, before it comes into contact with 
the lung surface and deposits on it. When it comes to pharmaceutical powders, which are of 
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interest within this work, the density of most drug substances is close to 1 g/cm3 and they do not 
possess unusual, for example needle shape unless intentionally done so. Therefore the geometric 
particle size of such dry powder for inhalation (DPI) formulations needs to be approximately in 
the above-mentioned  1 – 5 µm range. [4] Such small geometric sizes are usually achieved by jet 
milling or other micronisation processes. However, very small particles exhibit also poor 
flowability due to strong cohesion, which can lead to handling challenges during manufacturing, 
and thus they are commonly mixed with notably larger (≈ 100 µm) particles that serve as carriers 
for the drug substance particles. Frequently, the amount of drug that can reach the lungs using 
such formulations is rather low (usually 10 – 30% of the total dose). Low delivery efficiency 
means that a lot of the drug deposits in the mouth and throat, where it can cause for example 
hoarseness or irritation. The drug that does not reach the site of action in the lungs is eventually 
swallowed, causing possibly systemic side effects when the drug is orally bioavailable [5]. 
Another aspect for consideration might be the economic side as low delivery means that the 
expensive drug substance is mostly wasted and not used to its full potential. 
Particle engineering of pharmaceutical processes, such as of spray drying, offers a good way to 
address these disadvantages of the traditional DPI formulations. Spray drying is a rather simple, 
one-step process that allows control over particles properties like the geometric particle size and 
density. Particles can even be engineered in such a way that they have large geometric particle 
size and low density, while maintaining the aerodynamic particle size in the desired range [6]. 
Particles with these properties, often called large porous particles (LPP), can advantageously 
evade phagocytic alveolar clearance, which prolongs particles’ retention in the lungs. Also their 
handling might be improved thanks to reduced cohesion forces [7]. For successful production of 
low-density, porous or hollow particles, the particle engineering concept that is based on the 
Péclet number should be followed with the aim to create particles with high Péclet number [8]. 
Aside from spray drying process parameters, it is the excipients present in the feedstock that 
impact the particle size and its distribution, the density, cohesion, and aerosolization properties 
[9]. As the engineered particles do not use any carrier, their delivery efficiency into the lungs is 
often notably higher (commonly 60 – 80%). Despite the many advantages these engineered 
products bring, the amount of commercially available formulations leveraging on these processes 
is still very limited [10]. This is likely due to increased complexity as well as manufacturing costs 
such formulations have, which in cases where a suitable, notably cheaper alternatives exist might 
not justify their choice. Nonetheless they are used for formulations intended for systemic delivery 
as they can largely deposit in the lower respiratory tract where systemic absorption occurs. They 
also offer the possibility for pulmonary delivery of macromolecules such as proteins or peptides 
as they provide the stabilisation possibility for such rather fragile molecules.  
One of the biggest challenges contemporary pharmaceutical industry faces is poor water 
solubility of many new drug candidates that emerge from combinatorial screenings. Their share 
is said to be more than 50% and can be expected to rise [11]. Therefore, the techniques for 
formulating these “brick-like” drugs are in the spotlight of many companies as water is a common 
processing solvent. Water is of course also the basis for all dissolution media in the body and thus 
poor water solubility can negatively affect the drug’s bioavailability. Increasing the specific 
surface area of the drug by formulating it as nanoparticles, especially the closer the size comes to 
the 100 nm range, is one of the ways to address this issue. Many approaches exist for nanoparticle 
formation but in general they are of two-pronged character: either bottom-up, where the 
nanoparticles are built from the molecular structures (e.g. antisolvent precipitation), or top down, 
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where the nanoparticles are formed by particle size reduction. Industrially viable are mainly the 
top down techniques such as high pressure homogenisation or wet media milling due to more 
feasible scale up process. [12] 
Many of the drugs currently used for inhalation therapies do have poor water solubility (e.g. 
budesonide, fluticasone propionate, beclomethasone dipropionate). Though in most instances 
poor aqueous solubility of the inhalation drugs does not seem to pose such a critical property, as 
in case of orally delivered drugs, it can still be the main cause of slow dissolution kinetics and thus 
also poor absorption and low local bioavailability [13]. As means to improving the dissolution 
rate, such drugs could be processed to nanoparticles; though it ought to be noted that in the 
pharmaceutical field such term is often used for all submicron (< 1 µm) particles. However as 
implied earlier, nanoparticles are too small to be effectively delivered to the lung surface and are 
mostly exhaled [14]. Forming a composite microparticle composed of nanoparticles and matrix 
former(s) might be a solution to this obstacle. Forming a composite microparticle can be done for 
example by spray drying of a nanosuspension. Aside from dissolution rate and bioavailability 
enhancement, such composite dry powder for inhalation presents a formulation that also 
positively addresses concerns with drug distribution homogeneity, aerosolisation, drug loading, 
and particle size distribution. [9] Nanoparticles also support spray drying at high Péclet number 
due to their low diffusion coefficient, making them a suitable starting material for this engineering 
technique [8]. Though in few instances nanoparticles of poorly water soluble drugs have been 
already spray dried, this was not done with the aim to create a DPI formulation of optimised drug 
product performance by for example leveraging on the particle engineering principles such as the 
Péclet number consideration. 
Dissolution testing is a key assessment done for nearly any solid or semi-solid drug formulation 
as together with biological membrane permeability it guides the bioavailability of a drug for its 
action in the body. It can be also used as a quality control test to assess differences among the 
formulations of the same drug. Similarity of dissolution kinetics is one of the important 
requirements that in some instances oral generic formulations need to fulfil if sufficient 
equivalence between the original and the generic products wants to be claimed without a clinical 
bioequivalence trial. This is thanks to a well-established in vitro-in vivo correlation there exists 
for certain categories of oral products. However, this kind of correlation has still not been fully 
established for inhalation drugs. This is likely due to the complexity of the respiratory system and 
due to lack of any pharmacopoeial method that would allow relevant assessment of the 
dissolution kinetics despite the many years of research invested in this topic. [15,16] The problem 
of method development lies in finding a representative setup that would mimic well enough the 
dissolution conditions in the respiratory system. Depending on where in the lungs the particle 
lands, both the thickness and composition of the liquid as well as of the membrane are different. 
The lung liquid volume is generally very scarce as only a total of 10 – 70 mL is present in the lungs, 
spread over the vast lung area. [17] Additionally, particles do not deposit only in one particular 
place, rather they distribute along the pulmonary tree with a prevalence in either the central or 
peripheral area. The disease state usually also greatly changes the deposition pattern or lining 
liquid thickness and composition. And as mentioned above, removal of the particles from the lung 
surface by different mechanisms acting at the same time takes place. All these aspects make the 
development and validation of a dissolution test for inhalation products with claim of 
bioequivalence rather challenging. Several methods for dissolution testing of inhalation 
formulations have been utilised so far, leveraging mainly on modifying the USP2 method or using 
the Transwell cell culture supports, flow through cells, or Franz cells [18]. However, great 
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variability exists among the different methods in terms of dissolution medium volume and its 
composition. Some promising setups, such as with the Transwell inserts that mimic better the 
small lung liquid volume, do not mimic well the gradient caused in vivo by the absorption and 
transport into the epithelial cells, mucosa, or circulation. Also only rarely have powders of 
different aerodynamic particle sizes been compared and this was never done in a setup that 
would aim to closely mimic the in vivo conditions especially in terms of the dissolution volumes. 
Bioavailability-relevant is also the study of the drug fate upon its dissolution [15,19,20]. The site 
of action is rarely on the epithelial side of the lungs. Often, the drug needs to cross the epithelial 
membrane and bind to the receptors on the smooth muscles or to the nuclei in the epithelial and 
endothelial cells [21]. Variation in the disease-related changes such as in the airway morphology, 
pH, and viscosity of the epithelial lining fluid, and the near impossibility to take any samples at 
the site of action, make the study of the drug’s fate in a representative manner difficult. Animal 
and ex vivo models have to be still quite often used for study of in vivo fate as no in vitro models 
have so far been able to reliably substitute these ethically questionable approaches. Yet, many 
efforts are being put into in vitro models’ development with the aim to mimic closely the in vivo 
conditions. For example cell culture models grown at the air-liquid interface (ALI) [22] or co-
culture systems that contain also the phagocytic and/or dendritic cells have been developed [23]. 
A still rather new, yet very promising step further is the complex microfluidic-based lung-on-a-
chip device, which offers within an in vitro setup a more accurate representation of the in vivo 
physiology [24]. Unfortunately, due to its complexity it is less convenient to use in common 
research laboratory. Therefore, most often testing of particles’ fate is done using cell culture 
permeable supports. It is desirable to study aerodynamically classified powders to assess 
whether different particle size behaves differently. It is also beneficial to use cell models 
representative of where the particles would be expected to land, whether in the upper or lower 
respiratory tract. Aerodynamic assessment of inhaled formulations is described in 
pharmacopoeias and is commonly done using an impactor or impinger. Obtaining sample for cell 
culture testing from such device is however challenging as this requires modification of the 
device. Most research studies have so far utilised the old impinger system that however does not 
offer good classification possibilities. The most commonly used classification device, the next 
generation impactor (NGI), has never been modified to accommodate cell culture supports. 
  




The overall objective of this work was to engineer a poorly water-soluble drug substance, 
processed by wet media milling, into a composite dry powder inhaler formulation using the spray 
drying process and to create a formulation of enhanced drug product performance. The aim was 
to lay basis for this process combination so that it may become an industrially viable technology 
platform for processing of poorly water-soluble drugs. Further, the objective was to establish in 
vitro systems that closely mimic the in vivo physiology and that allow deeper study of the 
aerodynamically classified powder properties that are crucial for understanding particle 
dissolution and further fate upon particle’s deposition on a cell surface. For this, in vitro 
methodology based on combination of the next generation impactor with cell line was 
established. Figure 1.1 graphically summarises the contents of this work. 
As this work was multidisciplinary, bringing together pharmaceutical process development, dry 
powder formulation engineering, and in vitro cell culture testing in light of pulmonary drug 
delivery, the theoretical background laid down in chapter 2 covers the various fields necessary 
for better understanding of the work done and gives an overview of the state of the art including 
the persisting gaps there still are in terms of manufacturing process and formulation assessment. 
Attention is first paid to the pulmonary drug delivery, lung anatomy, and behaviour of particle 
upon inhalation as the key topics for understanding the requirements governing the formulation 
development and the restrictions related to this niche delivery system. Then, drug dissolution 
and its governing processes are described, and background is given on the particle size reduction 
as one of the ways of addressing poor dissolution kinetics. Dry powders for inhalation, their 
preparation and characterisation including the use of cell culture systems then complement the 
theoretical chapter, providing additional indispensable information relevant for this work. 
The aim of the pharmaceutical engineering part of the work was to utilise wet media milling and 
spray drying processes to prepare composite powders where nanoparticulate, poorly water-
soluble model drug substance would be embedded within a matrix, forming a microparticle of 
large geometric particle size and low density for enhanced aerodynamic performance and 
phagocytosis avoidance. The aim was to optimise each process to yield the best possible product. 
For wet media milling, the objective was to evaluate the role of the stabiliser (the type and 
concentration) and process parameters for creation of a stable nanosuspension, which was a 
prerequisite for the subsequent spray drying process. For spray drying, the goal was to develop 
a process that leverages the particle engineering principles and that supports spray drying at high 
Péclet numbers as means for creation of low-density particles. Therefore, the aim was to study 
the effect of matrix-forming additives of different diffusivity and solubility and to find their 
optimal concentration, hand in hand with studying the process parameters that support high 
Péclet number process. Further the aim was to explore usage of a pore former as an additional 
mean to lowering the particle density without the necessity to use an organic solvent since the 
overall goal was to utilise solely water throughout the whole manufacturing platform. Dissolution 
being a crucial prerequisite for drug’s successful biological action, a USP2 system was modified 
in order to assess the dissolution kinetics of five engineered, aerodynamically classified powders. 
Firstly, the optimal construction of the modified USP2 setup had to be identified in terms of 
polymer membrane material and dissolution medium volume. Once this was set, the objective 
was to understand how dissolution kinetics of the powder is affected on one hand by the different 
particle characteristics and on the other hand by the different deposition location. For the latter, 
three different impactor stages were always assessed within the dissolution setup. For thorough 
Introduction | Objectives 
6 
 
evaluation of the dissolution behaviour, the goal was to also employ a kinetic model. All the above-
mentioned  aspects are described in chapter 3. 
Immediately upon drug dissolution in the mucous lung liquid or surfactant layer, the processes 
of absorption, distribution, metabolism, and elimination start taking place. To study these in as 
much as possible representative manner, various in vivo or in vitro systems might be used. The 
aerodynamic particle size directly affects the place of particle deposition within the lungs and 
thus also the type of in vivo structures the particle interacts with. It is thus worth to 
aerodynamically classify the formulation for study of inhalation powder fate. The further aim of 
this work was therefore to modify the next generation impactor and to enable powder deposition 
on the air-liquid interface of surfactant layer of an A549 cell culture. This modification was done 
for the first time ever and allowed combining the state-of-the-art impactor with a cell culture 
deposition to study the particle-cell interaction. The goal was to study any effect of formulation 
composition and particle’s physical-chemical properties on the kinetics of the processes of 
particle dissolution in the surfactant layer, its uptake into the intracellular compartment and 
metabolism, and further transport into the apical layer. The aim was to as well apply the 
multicompartment kinetic modelling based on the cell physiology to delineate the processes. This 
biopharmaceutical characterization with impactor-cell culture combination is depicted in 
chapter 4. 
 








2  Theoretical background 
2.1 Pulmonary drug delivery 
Pulmonary drug delivery is a niche, lesser known delivery system that compared to oral drug 
delivery is being leveraged by rather limited number of pharmaceutical companies. Traditionally, 
it has been used for local delivery of small molecules (e.g. glucocorticosteroids) and only recently 
have there been advances in delivery of molecules for systemic delivery or in delivery of 
macromolecules to the lungs for local or systemic effect (e.g. insulin/Exubera®). 
Drugs are delivered to the lungs to achieve: 
 local treatment of lung diseases, such as of asthma or chronic obstructive pulmonary 
disease (COPD), which still represents the vast majority of inhalation applications, 
 systemic treatment thanks to drug absorption into the blood stream, which offers several 
advantages such as rapid onset of action, non-invasiveness, avoidance of first-pass 
metabolism convenience for drugs with low oral bioavailability, or needle-free delivery 
of biologicals that need to be applied parenterally [25], 
 targeting of specific lung cells (e.g. of alveolar macrophages for treatment of tuberculosis) 
Lungs however present a rather complex biological system, which as mentioned earlier is well 
equipped to prevent entry of any foreign material in order to ensure their correct primary 
function, the oxygen/carbon dioxide exchange. Of course, this exchange is vital for life and thus 
lung health should be of paramount importance for any human being. 
As with every drug delivery system, the physiology of the involved structures has to be properly 
understood in order to increase the chances of a successful disease treatment. Therefore, the next 
chapters are dedicated to understanding the basic lung anatomy, the aerosol deposition, and the 
aerosol interaction with the anatomic structures. 
2.1.1 Structure and composition of the pulmonary tree 
The pulmonary tree starts at the trachea and terminates at the alveolar sacs and along this way it 
bifurcates 23 times, creating a very large surface area of around 140 m2 [26]. It can be divided 
into the conducting and respiratory airways. The conducting airways (also referred to as 
tracheobronchial region) comprise the trachea, main bronchi, bronchioles, and terminal 
bronchioles, and act as a conduit for the inhaled air, which is filtered, warmed, and humidified in 
this region. The conducting airways bifurcate 17 times before reaching the respiratory airways. 
Respiratory airways (also referred to as alveolar region) are made by respiratory bronchioles, 
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alveolar ducts, and alveolar sacs (generations 17-23 in the bifurcating airway model), and they 
secure the exchange of oxygen/carbon dioxide between the alveolar space and the blood in 
alveolar capillaries  [27] (Figure 2.1). 
 
Figure 2.1 Overview of pulmonary tree structure [17]. 
The composition of the pulmonary tree greatly varies along its whole length (Figure 2.2). The 
upper part of the tracheobronchial region is composed of several types of cells such as the basal, 
goblet, ciliated, brush, serous, Clara, and neuroendocrine cells [28]. Also migratory cells such as 
lymphocytes, leukocytes and mast cells are present in this region. The terminal bronchioles, on 
the other hand, are only composed of ciliated cells and Clara cells. Alongside the cell composition 
change occurs also gradual epithelium thinning: epithelial cells in the trachea and bronchi are 
rather thick (50-60 μm in diameter) [25] while the terminal bronchioles measure only around 
10 μm. The surface of bronchial epithelium is covered by mucus, a viscous watery fluid with pH 
around 6.6 (in healthy individuals) that contains glycoproteins and proteoglycans. This fluid 
keeps the epithelium hydrated, humidifies the inhaled air to a relative humidity of 99.5% or more, 
contains antibacterial proteins and peptides, and protects the airways from inhaled chemicals 
and other xenobiotics [27]. Also, the conducting airways’ diameter changes dramatically with 
increasing generation number from 1.8 cm (tracheal diameter) to 0.06 cm (terminal brochioles’ 
diameter) [29].The cross-sectional area, on the other hand, does not increase tremendously in 
this region and reaches around 180 cm2 [4]. Clearance of foreign particles thanks to a mucociliarly 
escalator is the predominant removal mechanism in this region (chapter 2.1.3.3.12.1.3.3). 




Figure 2.2 Comparison of the lung epithelium at different sites within the lungs [2]. 
The surface epithelium in the alveolar region, on the other hand, is made of type I and type II 
epithelial cells (pneumocytes). The squamous type I cells are about 0.1-0.2 μm thin and cover 
around 93% of the alveolar surface. It is through these thin cells that the oxygen/carbon dioxide 
exchange occurs. The very small thickness of the alveolar epithelium is also favourable for the 
systemic absorption of drugs. Type II epithelial cells are cuboidal in nature, cover around 7% of 
the surface, and are thought to be precursors of type I cells during lung growth and repair [30,31]. 
They do however possess an important function as they are responsible for the production of the 
lung surfactant. The surfactant contains approximately 90-95% lipids, with 
dipalmitoylphopshatidylcholine (DPPC) as the main component, and 5-10% surfactant 
proteins[32]; however the composition may deviate in pathologic states. The lipids and proteins 
in the lining fluid reduce alveolar surface tension, increase the wetting, the solubility, and hence 
also the dissolution rate of poorly water-soluble drugs [33]. Furthermore, in this region are 
present alveolar macrophages, which phagocytise foreign particles or organisms (chapter 
2.1.3.3.2). Diameters of the alveolar airways do not change very much from generation 17 to 
generation 23 (Figure 2.1). However, it is in this region where the cross-sectional area increases 
enormously up to 10 000 cm2, especially thanks to the surface area of the alveolar sacs. 
2.1.2 Aerosol deposition 
Formulations used in pulmonary drug delivery are aerosols, i.e. small solid particles or liquid 
droplets, which are carried with inhaled air to the lungs. To understand the deposition in the 
lungs, it is beneficial to be first familiar with the general motion of particles in the air. 
2.1.2.1 Theoretical background 
Motion of any aerosol particle mostly occurs, due to its small particle size and low velocity, at low 
Reynolds numbers (Re < 1) where Stokes’s law applies. During settling, the gravitational force 
(FG) is equal and opposite to the drag force of the air on the particle, FD (2.1):  
𝐹 = 𝐹  (2.1) 
3𝜋𝜂𝑉𝑑 =
(𝜌 − 𝜌 )𝑑 𝑔
6
 (2.2) 
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where η is dynamic viscosity, V is particle velocity, d is particle diameter, and ρP is particle density 
[4]. Stokes’s law allows determination of the settling velocity of a particle, which is settling by 
gravitation in still air. Solving eq. (2.2 gives the terminal settling velocity VTS (eq. (2.3): 





which applies for spherical particles with sizes d > 1 µm and Re < 1. The settling velocity for 
particles with sizes d <1 µm is higher than predicted by Stokes’s law because the relative velocity 
of air right at the particle surface is not zero and a “slip” occurs on the surface of the particles. To 
account for this effect, a Cunningham correction factor CC (sometimes called slip correction 
factor) is applied and is always greater than one (eq. (2.5). The terminal settling velocity for 
particles with Re < 1 should therefore be written as: 













where 𝜆 is the mean free path of a gas, which is defined as “the average distance travelled by a 
molecule between successive collisions”. For instance, the mean free path of air at 20°C/1013 hPa 
is 0.066 µm. 
As aerosol particles are rarely perfect spheres, a shape correction factor ought to be applied to 
account for this. A dynamic shape factor χ, given by equation 6, is the ratio of the actual resistance 
force of the irregular particle to the resistance force of a sphere having the same volume and 
velocity as the irregular particle. 






where dE is equivalent volume diameter, i.e. diameter of a sphere having the same volume as the 
irregular particle. 
As χ is mostly > 1 (for example 1.08 for a cube), irregular particles settle more slowly than their 
equivalent volume spheres as follows from eq. 7: 
𝑉 =  





Since particles of different sizes, shapes, and/or densities can settle with the same velocity, an 
equivalent diameter that describes the aerodynamic behaviour of a particle, rather than its 
geometric properties, is commonly used in aerosol technology. Aerodynamic diameter, dA, is 
defined as the “diameter of a spherical particle with a density of 1 g/cm3 (density of a water 
droplet) that has the same settling velocity as the particle”. Using the aerodynamic diameter, the 
settling velocity of a particle is as follows (eq. 8): 
𝑉 =  
𝜌 𝑑 𝑔 
18𝜂
  (2.8) 




where 𝜌  is the unit density. After rearranging, the aerodynamic diameter of an irregular particle 





Figure 2.3 demonstrates graphically the concept of aerodynamic diameter. The particles shown 
in this figure behave aerodynamically the same due to equivalent settling velocities, which are 
the result of the particles’ size, density, and shape. 
 
Figure 2.3 An irregular particle and its equivalent aerodynamic sphere of the same settling velocity (adapted based on 
[4]). 
2.1.2.2 Aerosol lung distribution 
As it was mentioned earlier, only particles of a very narrow aerodynamic particle size range 
between 1 µm and 5 µm can actually enter the lungs. Deposition of the particles that do enter is 
essentially influenced by two groups of factors: those determined by properties of the aerosol 
(such as particle size, shape, density), and those determined by the patient (e.g. inspiration 
airflow velocity and volume, airway geometry, pause time between inspiration and expiration). 
The mechanism of deposition differs with the regions of airways. Most important ones are inertial 
impaction, sedimentation, and diffusion [1]. Only in certain situations (for example when needle-
shaped particles such as asbestos fibres are inhaled) are important also the less common 
mechanisms: interception and electrostatic precipitation [4]. 
 
Figure 2.4 Main deposition principle of particles upon entry of the lungs [34]. 
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Inertial impaction of particles is influenced by the geometric diameter and airflow velocity, and 
applies mainly to particles with dA > 3 μm (Figure 2.5) [35]. This mechanism is likely to occur in 
the upper conducting airways, where the velocity of inhaled air is high. Due to their inertia, large 
particles often fail to follow the air streamlines and impact on the epithelial wall, very commonly 
where the airway bifurcation occurs. The carrier particles, as well as very large drug particles 
(≈ 10 µm), usually impact in the throat and trachea, and are swallowed. 







where D is characteristic dimension of an obstacle and V is particle velocity[4]. Majority of the 
aerosol performance testing is based on impaction, and is described in more detail in chapter 
2.4.1. 
Sedimentation or settling via gravitational forces mostly influences particles between 1 and 3 μm 
and depends on particle mass and residence time. Particle around this size rage deposit both in 
the conducting and respiratory airways. Sedimentation is governed by the Stokes’s law and 
therefore a spherical particle will settle with settling velocity as per equation 8. 
Particles smaller than ≈ 1 μm are mainly subject to deposition via Brownian motion (diffusion). 
Diffusion coefficient (Df), which can be calculated from the Stokes-Einstein equation (eq. (2.11), 
is proportional to temperature and inversely proportional to particle size and air viscosity [36]. 
This mechanism dominates in the alveolar region, and breath holding may increase this type of 
deposition [37]. Yet, it has to be also noted that submicron particles are very often exhaled rather 
than effectively deposited in the lungs as the time requires for their diffusion and subsequent 





However, the given particle sizes are rather of an indicative character than strict cut-off diameters 
since the inhaled particles are distributed along the pulmonary tree (Figure 2.5). Additionally, 
even if primary particles are small, they might agglomerate into larger secondary particles and 
deposition in earlier generations if they do not disperse during the inhalation manoeuvre. 
 
Figure 2.5 Relationship between aerodynamic diameter and lung deposition [38]. 
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2.1.3 Fate of inhaled drugs upon deposition 
Once particles successfully deposit on the lung surface, several different actions might take place 
(Figure 2.6). After the deposition, particles start to dissolve in the lining fluid (chapter 2.1.3.1), 
which is the prerequisite for a deposited drug to be absorbed (chapter 2.1.3.2), to be bound on a 
receptor and/or be metabolised. At the same time, the particles can be cleared (chapter 2.1.3.3) 
by mucociliary clearance or phagocytised if deposited in the tracheobronchial or alveolar region, 
respectively. 
For inhaled, topically-active drugs, the ability to reach the site of action is dictated by the ability 
of the drug to dissolve in the lung fluid layer and by the transport mechanisms. Factors affecting 
these processes include the amount of drug deposited, as well as the location, solubility and 
mobility of the drug in the lining fluid, the particles’ deposition pattern, drug binding, 
permeability of the drug, and the residence time in the lung. 
In the oral delivery, a biopharmaceutical classification system exists [39] that helps to divide the 
expectations regarding drug’s in vitro-in vivo correlation based on its solubility and permeability 
as the key properties. Though some attempts have been made to establish similar system for 
pulmonary delivery (e.g. by Eixarch [40]), no reliable system has been developed up until today. 
Details of the challenges are discussed further in this chapter. 
 
Figure 2.6 Possible routes of drug elimination from the lungs in the tracheobronchial region [41]. 
2.1.3.1 Dissolution 
Dissolution rate is an important attribute that influences drug bioavailability together with 
attributes such as drug saturation solubility, permeability, and dose and deposition pattern. 
Saturation solubility of a drug depends on the compound itself and its solid form as well as on the 
composition and volume of the lung fluid [42]. Dissolution rate depends in addition to solubility 
also on the cross sectional area of the drug particles, the drug surface properties, and the volume 
of the lung fluid, as well as on the hydrodynamics of mixing in the lungs, as given by the Noyes-
Whitney/Nernst Brunner equation. This equation is in greater detail described in chapter 2.2. The 
total liquid volume in human lung is only around 10-70 mL [17,43]. This volume is, of course, 
spread over the large surface area of the lungs as a thin film rather than being a bulk volume, 
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which leads to very small volumes being effectively available for dissolution of the deposited 
drugs. 
It could be assumed that similarly as for oral drug delivery, also inhalation drugs can be 
dissolution-rate and permeation-rate limited. However, dissolution-rate limitation is for several 
reasons not seen as often [13]. For one thing, the drug particle size is in pulmonary delivery, 
compared to oral delivery route, rather small, which aids faster dissolution due to increased 
specific surface area. For second thing, the required dose seen with most of the inhaled drugs, 
such as the short-acting and long-acting bronchodilators, is rather small (in micrograms range) 
(Figure 2.7). 
Additionally, the knowledge about the aspects affecting drug dissolution in the lungs is still very 
limited due its complexity and the difficulty to study this drug delivery method [43]. 
2.1.3.1.1 Tracheobronchial region 
The liquid layer volume and thickness ranges 10-30 mL and 5-10 μm, respectively, in the 
tracheobronchial region [44]. Most of the currently marketed small molecule drugs for inhalation, 
including the mentioned bronchodilators, target this lung region. These drugs are not dissolution 
limited as their saturation solubility in the 10-30 mL is sufficient for the required dose. These are 
the drugs located above the band in Figure 2.7. 
Dissolution-rate limitation is seen with two groups of drugs: 1) corticosteroids such as fluticasone 
propionate (FP), beclomethasone dipropionate (BDP) or mometasone furoate (MF) due to their 
very low solubility, and 2) antiinfectives of limited solubility (< 100 µg/mL) such as ciprofloxacin 
betaine or amphotericin B, whose required dose is very high. These are the drugs below the band 
in Figure 2.7. Permeability-limited drugs, on the other hand, might be dissolving under lack of 
sink conditions due to their accumulation in the mucus layer. 
The lung fluid composition could also have a positive effect on the drug solubilisation due to 
presence of various salts, phospholipids, proteins, and mucins [45]. 
 
Figure 2.7 Solubility of pulmonary drugs vs. the required dose in the conducting airways [46]. 
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2.1.3.1.2 Alveolar region 
Drugs targeted to the alveolar region are usually intended for their absorption into the systemic 
circulation. As described earlier, the liquid layer thickness gradually decreases with increasing 
generation number and eventually reaches only 0.01-0.08 μm. However, this layer is surfactant-
like in nature as it consists mostly of lipids. This potentially improves solubilisation of low 
molecular weight drugs (i.e. not macromolecules) that do reach this region. Thanks to the thin 
epithelial layer, the dissolved substances are likely quickly absorbed into the blood stream and 
thus sink conditions are easily maintained. 
2.1.3.2 Transport to site of action 
Lungs are used to treat both local as well as systemic diseases and thus the site of action a drug 
needs to reach depends on the disease that is being addressed. In general, compounds that 
dissolve upon deposition on the lung surface and are not cleared can be transported across the 
cell membrane via different pathways [47]: 
 transcellular passive diffusion, 
 paracellular passive diffusion, 
 carrier-mediated uptake at the apical side followed by passive diffusion across the 
membrane, 
 vesicle-mediated transcytosis, and  
 transporter-mediated uptake or efflux. 
It has been shown by Schanker et al. [48,49] that most low molecular weight compounds are 
absorbed by passive diffusion. They have also shown that the rate of absorption increases with 
lipophilicity for compounds with partition coefficient from -3 to 2. Nature of the drugs also affects 
the speed with which they are absorbed: as a rule of thumb, lipophilic drugs with a log P > 0 show 
rapid absorption times (≈ 1 min), while hydrophilic drugs with a log P < 0 have notably longer 
absorption times of ca 1 h [46]. It has been also shown that the upper size limit for particles to be 
transported by clathrin-mediated endocytosis is approximately 200 nm, which is relevant for 
delivery of slowly soluble nanoparticles [50]. Current research of macromolecules suggests that 
proteins can be transported across the alveolar epithelium both transcellularly (e.g. endocytosis) 
and paracellularly with the molecular weight of the macromolecule affecting greatly the transport 
mechanism type [1].  
2.1.3.2.1 Tracheobronchial region 
The tracheobronchial region is targeted mostly for local treatment of diseases such as asthma, 
COPD, or cystic fibrosis. It is therefore the local bioavailability that is of interest when targeting 
this region. The drugs’ mode of action is often of bronchodilative or mucolytic character. The 
drugs affect either the mucus composition or the smooth respiratory muscles, which are located 
between the epithelium and the blood vessels (Figure 2.6) [51]. Also antibiotics might be 
administered to the endobronchial region, usually for treatment of comorbid infections, such as 
by Pseudomonas aeruginosa, due to hypersecretion of mucous and its reduced removal in cystic 
fibrosis patients [52]. 
The receptors for these drugs are located either on the cell surface or inside of the cells. The drug 
solute thus has to pass through this cellular barrier, which is in the bronchi composed of a rather 
thick monolayer of columnar cells (Figure 2.8) [1,27]. Due to the thickness of the conducting 
airways, the distance to reach blood vessels is rather long and therefore only small portion of the 
drug enters the systemic blood circulation. 




Figure 2.8 Schematic drawing of the bronchial and alveolar physical absorption barrier [53]. 
2.1.3.2.2 Alveolar region 
On the other hand, the alveolar region is typically targeted to achieve systemic drug absorption 
thanks to the small thickness of alveolar epithelial barrier and the vast blood-capillary network. 
The cell monolayer is made of thin, broad cells with the distance between the respiratory tract 
and circulation being approximately 500 nm (Figure 2.8) [1,27]. The advantage of using lungs for 
systemic delivery of small molecules (e.g. nicotine, morphine, fentanyl) is that it offers fast action 
onset, non-invasiveness, low metabolism, and high systemic bioavailability [2,54]. For example, 
an inhaled levodopa formulation has been recently (2019) approved in Europe for use in 
Parkinson’s disease, showcasing the attractiveness of this approach [55]. The systemic 
bioavailability can be considerable also for biological macromolecules (e.g. insulin, heparin, 
growth hormone), however this largely depends on the biomolecule’s molecular weight. Up to 
30 kDa, the bioavailability is 20 – 50%; however can be notably lower for some molecules due to 
degradation upon their deposition (e.g.by enzymatic hydrolysis, proteolysis). This might be 
addressed by formulation composition such as by the addition of absorption enhancers or 
protease inhibitors to the formulation. [56] 
2.1.3.3 Clearance 
As Hastedt et al. [46] well said “In contrast [to gut], the lungs are designed to remove foreign 
material in order to maintain gas exchange”. Thus, instantaneously as an inhaled formulation 
starts to dissolve, the defence mechanisms try to remove it from the lung surface. 
2.1.3.3.1 Tracheobronchial region 
Particles deposited in the conducting airways are rapidly (t½ ≈ 1-1.5h [57]) cleared by the 
movement of mucus up towards the trachea and subsequently pharynx, where they are either 
swallowed or spat out. This process is known as the mucociliary escalator and is ensured by 
coordinated beating of the ciliated cells. Coughing greatly enhances mucus clearance by moving 
the mucus faster to pharynx, while failing to clear mucus can lead to obstruction and infection 
[27]. 
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2.1.3.3.2 Alveolar region 
Since the composition of alveolar region is completely different from tracheobronchial region, 
also the defence mechanism against the foreign particles differs. Clearance of any insoluble or 
slowly soluble particles deposited in the alveoli is ensured by phagocytosis done by alveolar 
macrophages. On average, in each alveoli are 12-14 macrophages that ensure this clearance [58]. 
Their action is rather fast: majority of particles (50-75%) was shown to be phagocytised in 2-3 h, 
more than 90% by 12 h and almost 100% by 24 h [58,59]. After phagocytosis, the alveolar 
macrophages remove the particles by either enzymatic degradation, translocation into the 
lymphatic system, or by moving them towards the ciliated cells [60]. 
Interestingly, effectiveness of macrophage phagocytosis depends on the geometric particle size. 
It is most effective for particles with geometric size in the range between 1.5 and 3 µm, while 
particles with size < 1 µm and >4 µm were found to have reduced uptake [61]. For comparison, 
the average nuclear size of a human alveolar macrophage is ≈ 8 µm [62]. The particle surface 
composition also plays a role in the extent of phagocytic clearance. Makino et al. [63] studied the 
effect of functional groups on the microsphere surface on the macrophage uptake using 1 μm 
polystyrene particles with primary amine, sulfate, hydroxyl, or carboxyl groups on their surfaces. 
This study showed that microparticles with primary amine groups were phagocytosed to largest 
extent, microparticles with carboxyl groups to slightly lower, and other microparticles to much 
less extent. 
2.2 Drug dissolution 
Drug dissolution is generally a two-step process: in the first step, the drug molecules are solvated 
by the solvent at the solid-liquid interface, while in the second step are the solvated molecules 
transported from the interface into the bulk solution. The first step is controlled by the drug’s 
solubility in the solvent. The second step is then controlled by the transport (diffusion and 
convection) of the drug molecules [64]. Diffusion rate is influenced by the diffusion coefficient, 
boundary layer thickness. It depends also on parameters such as dissolution medium agitation 
intensity, temperature and viscosity, particle size [65]. 
The dissolution rate (dm/dt) of a solid substance in a liquid medium can be described by the 






(𝐶 − 𝐶) (2.12) 
 
where m is dissolved drug amount, t is time, D is diffusion coefficient, S is surface area of solid 
substance, h is thickness of diffusion boundary layer, Cs is saturation solubility of drug in the 
medium, and C is concentration of dissolved drug in the medium. 
The dissolution process can be limited by either of the two above-mentioned steps. However, it 
is usually the diffusion that limits the dissolution since molecules have to translocate across large 
distances compared to molecular dimensions, which are involved in the first solvation step [64]. 
However, for poorly soluble drugs also solvation can be the limiting step instead. This occurs 
when the equilibrium solubility (eq. (2.12) is very low in the given medium (Figure 2.7). The 
surface specific dissolution rate of such poorly soluble drugs can be positively influenced by the 
decrease in particle size, which directly increases the specific surface area. Additionally, it was 
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suggested that as well the particle shape can affect the dissolution rate in such a way that irregular 
particles show lower dissolution rates [68]. 
The most common techniques for dissolution rate enhancement of poorly-water soluble drugs 
either focus on chemical modification (e.g. salt or co-crystal formation, complexation with 
excipients) or on physical modification of the drug such as the particle size reduction or crystal 
habit change (e.g. polymorphic change, formation of amorphous solid dispersion) [69]. 
2.2.1 Particle size reduction 
Particle size reduction by micro- and nanonisation is one of the frequently applied techniques for 
improvement of dissolution rate and is one of the few techniques that does not require change in 
chemical composition of the drug. Though when applied to create nanoparticles, it is often 
desirable to use stabilizers to prevent agglomeration and crystal growth, which occur as a results 
of the system trying to reduce its free Gibbs energy. This makes the nanocrystals 
thermodynamically unstable causing Ostwald ripening or particle agglomeration. [70] Particle 
size reduction to nanosize range is especially of interest for dissolution rate enhancement since 
the specific surface area dramatically increases below 1 µm (Figure 2.9) due to its inverse 
proportionality to particle size. 
 
Figure 2.9 Specific surface area as a function of particle size [71]. 
The particle size reduction and to it related increase in the surface curvature can also marginally 
improve the dissolution rate by increasing the solubility of nanoparticles as described by the 
Ostwald-Freundlich equation: 




where Cr and C∞ are the solubilities of a particle of radius r and of infinite size. γ, M, and ρ are 
interfacial tension at the particle surface, the molecular weight of the solute, and the density of 
the particle, respectively [72]. 
2.2.2 Drug nanoparticles 
Drug nanoparticles have gained importance in pharmaceutical research and industry in the 
recent years, as evidenced e.g. by numerous wet media milled drug products for oral and 
parenteral use on the market [73]. 
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The techniques for production of nanoparticles are of two characters: top down, where 
nanoparticles are created by breakage of larger particles, or bottom up, where nanoparticles are 
built from molecular scale [74]. Top down approaches include milling (e.g. wet media and jet 
milling) and homogenization (e.g. high pressure, jet stream, piston-gap). Bottom up approaches 
include solvent evaporation and precipitation techniques for example by dissolving the drug  in 
a solvent to supersaturation level and inducing precipitation by adding an antisolvent [12,75,76]. 
Most commonly, the nanoparticles are maintained suspended in a liquid, forming a 
nanosuspension. Nanosuspensions have the potential to provide high drug load as they might 
contain as little as 10% of stabiliser [77]. Typical stabilisers used in wet media milling, which was 
employed within this work, are Poloxamer 188 and 407, Polysorbate 80, D-α-tocopherol 
polyethylene glycol 1000 succinate (TPGS), cellulosics, polyvinylalcohol, or sodium 
dodecylsulphate [78]. Stabilisers however usually provide only short or medium term stability. 
In order to achieve long term stability, it is desirable to dry the nanoparticles into a powder. This 
is usually done using the freeze or spray drying techniques (chapter 2.3.1.2.1). 
2.2.2.1 Wet media milling 
Wet media milling represents one of the commonly used top-down approaches for nanoparticle 
production. During the milling process, the suspended material is ground by shear and 
compression forces between the grinding media, which is given kinetic energy from a rotating 
shaft and stirring elements. The specific energy input (Em,P) of the process is proportional to the 
number of milling stress events and their energy. The milling stress events are affected by the 
milling time and the grinding media’s amount, density, size, and relative velocity [79]. The 
information on the specific energy input can be calculated by application of equation (2.14: 
𝐸 =
∫ (𝑀(𝑡) − 𝑀 )𝜔𝑑𝑡
𝑚
 (2.14) 
where M(t) is the torque measured during milling, M0 is the no-load torque, ω is the stirrer 
angular velocity, and mp is the product mass. 
 
Knowledge of the specific energy is crucial for the outcome of the process, experiment 
repeatability, and process scale up. The milling result is affected also by the operation mode of 
the mill, by the formulation of the suspension as well as the mill geometry. Numerous poorly 
water-soluble drugs have been nanomilled in the last 15 years [80] with median particle sizes 
ranging from < 100 nm [81] to ≈ 650 nm [82] or even larger in screening studies [83]. 
Unfortunately, only few studies [84–87] related the obtained nanoparticle sizes to the Em,P. 
2.3 Dry powders for inhalation 
Chapter 2.1 described the theory of aerosol deposition as well as subsequent fate of the particles 
in the lungs. However, an understanding of the aerosol formulation preparation and its properties 
as well as characterisation is still missing. 
There are three major types of inhalers that can be used for delivery of drugs to the lungs: 
nebulisers, pressurised metered dose inhalers (pMDIs), and dry powder inhalers (DPIs). In 
nebulizers, the drug is suspended or dissolved in water, whereas in pMDIs it is suspended or 
dissolved in a liquid propellant. The propellant is typically a hydrofluoroalkane and is kept under 
pressure in a canister. Dry powder inhalers are devices where the drug powder or drug-
containing powder is stored in a capsule or reservoir. In DPIs, the patient’s inspiration provides 
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energy for aerosolisation of the powder bed. Unlike the pMDIs, they do not require coordination 
of actuation and inhalation. They are also environmentally friendlier due to lack of any propellant. 
However, the delivery greatly depends of patient’s inspiratory flow and as in case of all the inhaler 
types, on correct inhaler use. [88] 
Irrespective of the inhaler type, the formulation should have upon dispersion aerodynamic 
particle size distribution (APSD) favourable for successful deposition in the target area of the 
lungs (Figure 3.7.) As mentioned, it is widely accepted in the scientific community that the 
aerodynamic particle size range for efficient pulmonary delivery is 1-5 μm. This range has been 
assessed based mainly on in vivo studies of radiologically labelled formulations.[35] As indicated 
in equation 9, the aerodynamic particle size depends mostly on the equivalent volume diameter, 
which is then greatly guiding the formulation performance. 
There are two approaches for preparation of dry powders for inhalation – traditional, carrier-
based approach, and an engineering approach. Majority of the marketed DPI formulations use the 
traditional system where small drug particles cover surface of a much larger carrier, usually 
lactose. During inhalation part of the drug deagglomerates and enters the lungs. Since the drug 
particles have density close to or slightly greater than 1 g/cm3, the aerodynamic particle size is 
larger than the geometric particle size of the drug particle. 
The engineering approach is currently used only in very few marketed products (e.g. TOBI® 
Podhaler™, Colobreathe® Turbospin) [89] and relies on the large porous particles [6]. In this 
approach, the drug is embedded within an engineered particle, which usually comprises also 
other excipients. The density of such particles is typically a lot smaller than 1 g/cm3, which allows 
the geometric particle size to be larger than in case of the traditional approach, while achieving 
same aerodynamic properties as smaller but denser particles. 
2.3.1 Preparation of dry powders for inhalation 
2.3.1.1 Traditional approach 
Most traditional DPI formulations contain either drug particles alone or blend these with a carrier 
(Figure 2.10). The drug is usually micronised by jet milling to achieve the respirable particle size 
range of 1-5 µm. However, this process can yield highly cohesive powders and offers only limited 
control over the particle size distribution and morphology. To help deaggregation of the usually 
rather cohesive particles, the drug is often blended with a much larger carrier (e.g. lactose with 
median particle size ≈ 100-150 µm) to form an adhesive mixture. Here, the interactions between 
the drug and the carrier have to be balanced to ensure that the mixture is on the one hand stable 
and homogenous throughout the production process (such as blending, encapsulation, blistering) 
but on the other hand allows detachment of the drug from the carrier during inhalation. To 
improve even more the performance of these formulations, force control agents (e.g. magnesium 
stearate, lactose fines) are sometimes added to the blends [51,90,91]. 
Although well-established, this system does not allow high drug load and the fraction of drug 
delivered to the lungs is usually rather low (10-30%) [92,93]. 




Figure 2.10 Principle of carrier-based, traditional dry powder inhaler formulation [88]. 
2.3.1.2 Engineering approach 
Another approach for preparation of DPI formulations is to use bottom up techniques such as 
spray drying, freeze drying, or supercritical fluid technology. These techniques offer better 
control of the particle size distribution and morphology and allow also formulation of therapeutic 
biomolecules. For example freeze drying has been advantageously used for production of large 
porous particles that have large geometric size (up to 20 µm) but thanks to low density ≈ 0.1 
g/cm3) reach desirable aerodynamic sizes for high lung deposition (50-60%) [6]. Theoretically, 
geometrically large particles should also have smaller contact area and thus lower extent of 
cohesive forces between the particles [94], which should improve handling and dispersibility 
[95]. However, for this effect to be pronounced the difference in the particle size would likely have 
to be in the orders of magnitude rather than increase by units of micrometres. The drug loading 
of these particles as well as fraction of the delivered drug dose is usually higher (40-70%) [93]. 
Great benefit of this approach is also that one can embed drug nanoparticles within the 
microparticles and deliver them to the lungs. This is important especially for poorly water-soluble 
drugs, whose dissolution can be enhanced by the particle size reduction (chapter 2.2). Spray 
drying is often the process of choice for production of engineered particles [89]. 
2.3.1.2.1 Spray drying 
Spray drying is a rather versatile, one-step process in which a liquid feedstock is within 
milliseconds transformed into dry powder. It has three distinct stages: atomisation of feedstock 
into droplets, droplet drying, and solid particle collection. Atomisation guides to a large extent 
the initial droplet particle size. Right after the atomisation, a droplet is formed and the solvent 
starts to evaporate. Initially, the droplet size does not decrease much as the droplet temperature 
increases to its wet-bulb temperature. After this, the solvent starts to rapidly evaporate and the 
droplet shrinks. Depending on the solutes’ critical supersaturation concentration, a skin 
formation occurs and the particle quickly solidifies [96]. 
In spray drying, the droplet evaporation and particle formation kinetics are governed by coupled 
heat and mass exchange processes [96], which can be influenced directly or indirectly by the 
process and feedstock properties. Among the process properties belong inlet and outlet 
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temperature, drying gas flow, and atomising pressure. Feedstock properties are feedstock flow 
rate, solids content, as well as solutes’ saturation levels. 
The drying process can be described by a dimensionless Péclet number (Figure 2.11) [8]. This 
number (eq. 2.15) compares the rate of droplet surface reduction (i.e. evaporation rate κ) to the 
diffusion of the solutes in the droplet (Di) [96]. The evaporation rate is directly related to the 
temperature of the drying gas and its relative humidity, while the diffusion coefficient controls 






Particle formation theoretically occurs at low or high Péclet numbers. In both cases, as the droplet 
shrinks, the solute concentration close to the droplet surface increases. The result of the drying 
however depends on the Péclet number: 
a) Drying at low Péclet number (Pe < 1) occurs when the evaporation is slower compared to 
the diffusion of the solutes. During such drying process, the solutes have enough time to 
diffuse along the concentration gradient from the droplet surface towards inside of the 
droplet. Thus, solid particles with density close to the skeletal density of the solute are 
likely to form. 
 
b) If the evaporation is faster than the diffusion of the solutes, the Péclet number is larger 
than 1. The solutes, which are in higher concentration close to the surface of the droplet, 
do not have time to diffuse and thus precipitate and create a shell. [8,98] Density of such 
particles is naturally smaller than the skeletal density. Also spray drying of suspended 
(nano)particles follows similar path because the suspended material can be considered 
immobile compared to the receding droplet surface [8]. When producing the low-density 
particles in this way, one can use either a high molecular weight solute, which intrinsically 
has a small diffusion coefficient, or a solute that precipitates quickly in the drying process 
and thus becomes immobile (form example leucine, trileucine [8]). Successful formation 
of a shell composed of nanoparticles has been proven to be possible numerous times [98–
100]. 
 
Figure 2.11 Péclet number representation (r is the droplet radius, t the droplet drying time, Di diffusion coefficient of 
solute). 
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However in reality, the diffusion coefficient of a component changes with concentration and 
composition of the solvent. Hence, the Péclet number changes as the droplet evaporates [8]. 
Application of particle engineering in spray drying thus allows tailoring both the geometric 
diameter as well as the particle density. The diameter can be tailored mostly by controlling the 
droplet size through atomising pressure in the spray nozzle and, to lower extent, by the feed 
solution concentration. Density, on the other hand, can be lowered by choice of drying conditions 
and formulation properties that support drying at high Péclet numbers [8]. 
2.3.2 Use of particle engineering for DPI formulation manufacturing 
The possibility to control the resulting particle properties is very beneficial for tailored 
manufacturing of DPI formulations. Aside from an improved aerodynamic performance, the 
aerodynamic particle size can be tailored to some extent to target either more the bronchial or 
the alveolar region by changing the APSD profile. 
Larger geometric particle size is also beneficial as the drag force increases linearly with geometric 
particle size (chapter 2.3.4.2). Compared to force of gravity, the drag force FD of particles <10 µm 
is at least four orders of magnitude higher than FG even at relatively low air velocities of 20m/s. 
Therefore, even at the same aerodynamic particle size, the chance to remove by an air stream a 
larger adherent particle from a surface is higher compared to a smaller one [101]. Additional 
benefit of larger geometric particle size can be the expected reduction of phagocytic clearance in 
the alveolar region, which as described earlier is a size-driven process (chapter 2.3.3.2). 
Particle engineering by spray drying has been successfully utilized numerous times using many 
different drugs [102–107]. Duddu et al. [108] for example prepared PulmoSpheresTM (same 
technology as used in TOBI® Podhaler™) budesonide formulation that is able to deliver 57% of 
the nominal drug dose. Excipients such as phospholipids (distearoyl phosphatidylcholine, DPPC), 
lipids (cholesterol, lecithin), or amino acids (leucine, glycine) were often employed as well as 
various solvents (ethanol, methanol isopropanol, dichloromethane). The usage of the solvents is 
of concern since organic solvents have no therapeutic benefit, inherently have a certain level of 
toxicity, and cannot be fully removed from the product. Therefore, their usage should be limited 
as much as possible and their residual levels need to be closely monitored as instructed by the 
ICH Q3C guideline [109]. Thus, avoiding the organic solvents completely is the safest option at 
hand. Large porous particles have been mostly produced by spray drying of a double emulsion 
with various excipients as matrix formers (e.g. poly(lactic-co-glycolic) acid, cyclodextrins, DPPC 
in combination with hyaluronic acid or other excipient) [110]. Most often, the drug in such 
formulations was either dissolved in water or in any of the co-solvents, or used as drug 
suspension. Less frequently were the drugs, especially poorly water-soluble ones, pre-processed 
to nanosize range [111]. 
Despite the numerous advantages the engineering approach has, it is rarely used in the 
pharmaceutical industry since drying the technologies required for particle engineering are 
considerably more expensive than the techniques applied within the traditional approach. The 
high production costs would of course reflect in the commercial drug product price, which might 
not be competitive for the common respiratory diseases. 
2.3.3 Pulmonary delivery of nanoparticles 
The challenge in effective delivery of nanoparticles to the lungs is that, under normal 
circumstances, nanoparticles are too small to deposit in the lungs (Figure 2.5). Once inhaled, 
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nanoparticles are very likely to be exhaled as the time required for their deposition by diffusion 
is greater than the breath-holding time. 
However, similarly as microparticles, nanoparticles can still be delivered into the lungs by 
inhalation of a colloidal suspension, or as dry powders. Nebulised formulations can consist of 
stabilised nanodispersion, powders for redispersion before usage, or drugs encapsulated in 
polymeric or lipid nanoparticles [75,112]. Solid formulations are usually preferable as they 
ensure better physical and chemical stability due to limited molecular mobility [112]. In the dry 
state, nanoparticles can be delivered to the lungs by using: 
 composite microparticles with drug nanoparticles 
 composite microparticles that contain nanoparticles with drug encapsulated within the 
nanoparticles, 
 neat nanoparticles aggregated into microparticles. 
2.3.3.1.1 Composite microparticles with drug nanoparticles 
In this approach, which has been applied also within this work, the drug itself is in the form of a 
nanoparticle. The drug nanoparticles are then with help of excipients (amino acids, sugars or 
phospholipids) formulated in a subsequent process into microparticles [25]. Freeze- and spray 
drying are commonly used processes for microparticle formation. The advantage of this approach 
is that thanks to the nature of the nanoparticles the drug load can be maintained rather high and 
is not affect by encapsulation efficiency. The presence of excipients can on the other hand aid to 
dissolution of the microparticle once it lands on the lung surface. 
2.3.3.1.2 Encapsulation of drug into nanoparticles 
In this type of formulation the drug substance is encapsulated into nanoparticles. In the past, very 
often the drug was loaded into purchased or prepared nanoparticles made out of polystyrene, 
polyacrylate, colloidal silica, chitosan/tripolyphosphate, gelatin, or biodegradable polymers such 
as poly(butylcyanoacrylate) and poly(lactic-co-glycolic acid) [113–116]. Among the explored 
drug substances, which have been loaded into the polymeric nanoparticles, were for example 
aspirin and salbutamol sulphate [100], doxorubicin [114], ciprofloxacin [115], or 
macromolecules [117,118]. Loaded nanoparticles were usually dispersed in a matrix carrier (e.g. 
lactose, mannitol, trehalose) and spray dried. The encapsulation efficiency is however usually 
rather low, limiting greatly the amount of drug that can be delivered at once. 
2.3.3.1.3 Nanoparticles aggregated into microparticles 
As aggregated nanodrugs have been formulated mainly, but not only, poorly water-soluble drug 
substances, e.g. terbutaline sulfate [119], salbutamol sulfate [120], nifedipine [121], itraconazole 
[122], or paclitaxel [123]. Such formulations contain only the drug and possibly a stabiliser and 
are aimed to be hollow or porous. Thus, when prepared by spray drying, they adopt low density 
owing to very low mobility of the nanoparticles compared to evaporation rate. 
2.3.4 Forces in powders 
During manufacturing and administration of a DPI formulation, the powder particles are exposed 
to several forces irrespective of the adopted formulation approach. During the manufacturing, it 
is mostly the attractive interparticulate forces (of cohesive or adhesive character) that keep the 
particles together and possibly cause particle agglomeration to greater or lesser extent (chapter 
2.3.4.1), while during usage forces that cause the particles’ dispersion upon inspiration also play 
a key role (chapter 2.3.4.2). Fine balance between these forces needs to exist especially within 
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the traditional approach where the formulation has to remain homogenous and flowable 
throughout the manufacturing process but it also needs to successfully aerosolize during 
inhalation [124]. Homogeneity is less of a problem for the engineered formulations as each 
particle composition should be, theoretically, the same. However, as these formulations contain 
very fine particles (< 10 µm) flowability can pose a challenge during manufacturing. 
2.3.4.1 Forces affecting particle cohesion/adhesion 
Inhalation dry powders are formulations of ideally homogenous character in which attractive 
forces between the particles (drug-drug, drug-carrier, spray dried particle-spray dried particle) 
naturally exist. They can be of cohesive or adhesive character, depending on the surface energies 
of the system components. In the carrier-based formulations, they are responsible for adhesion 
of the drug particles to the carrier surface and it is desirable that they are strong enough to ensure 
formulation homogeneity. The extent of the attractive forces depends on many factors such as 
(but not only) particle size, shape, surface roughness and morphology, density and porosity, 
moisture content [125–127]. The cohesion forces are in fact directly proportional to the particle 
diameter (Figure 2.12). 
Among the most common attractive interparticulate forces experienced by DPI formulations are 
van der Waals, electrostatic (which can be also repulsive), and capillary liquid forces. The van der 
Waals and capillary forces are major attractive forces for particle sizes < 10 µm [101]. The 
capillary forces are the dominant forces above a critical RH level (65-70%) [51,128]. As the 
relative humidity during formulation production can be controlled, it is mostly the van der Waals 
forces that cause agglomeration of small particles and lead to poor flowability and dispersibility 
of powders made of such particles. These forces are caused by the dipole-dipole interactions of 
the molecules and play role when the separation distance between the surfaces is below 50-100 
nm [101,129]. The overall van der Waals forces will increase with increase in the surface contact 
area as in case of e.g. two flat surfaces [130]. For this reason, it is advantageous to formulate DPI 
formulations as spray dried powders, or blend the drug particles with carriers as done within the 
traditional approach, to prevent extensive agglomeration and improve dispersibility [131]. The 
dispersibility of the spray dried particles can be improved even further when the particles have 
corrugated surface as this lowers the contact area even more [101,132]. 




Figure 2.12 Left: Theoretical cohesion forces of two contacting, rigid, insulated, and spherical particles. Right: 
Theoretical forces influencing the separation of adhering spherical particles.[101] 
2.3.4.2 Forces affecting particle aerosolisation 
Particle of sizes < 10 µm are mostly influenced by the above-mentioned cohesive forces and 
gravitational forces are more pronounced only for particles in the upper micron-size range 
(Figure 2.12). Powder aerosolisation, caused most often by an air stream from patient’s 
inspiration, puts energy into an otherwise static powder bed and leads to powder fluidisation. At 
the same time, a drag force acts on the adhered particles within the powder. When the drag force 
is greater than the attractive interparticulate forces, it leads to successful particle detachment 
and inhalation of the drug or drug-containing particle. The drag force increases linearly with 
particle size at Re < 0.5 and exponentially with higher Re. This leads to higher chance of particle 
detachment in case of larger particles compared to a smaller one [101]. However particles 
< 20 µm are difficult to aerosolise as they lift as an agglomerate due to the interparticulate forces 
being considerably larger than the drag forces [133,134]. The aerosolisation efficiency is in 
practise directly related to the inhaler’s resistance and the inspiration flow rate [131]. 
2.4 Characterization of inhalation powders 
Just as any pharmaceutical product, also powders for inhalation are tested to assess their quality 
and to ensure that the patient receives the expected drug dose. Health authorities commonly 
require monitoring of the delivered dose uniformity and fine particle dose in the inhaled drug 
products, as well as their adequate quality [135]. Other tests might be given by certain 
international bodies and their guidelines, such as the ICH [109]. 
Further tests like physical-chemical characterization (e.g. particle size distribution, water 
content, X-ray powder diffraction, etc.) or blend and content uniformity of the drug product might 
be performed to ensure control over some of the above-mentioned  aspects. Other tests like a 
dissolution test might be done to not only control the product quality but also to study the drug’s 
release kinetics and to potentially draw conclusion on bioavailability in case an in vitro-in vivo 
correlation (IVIVC) has been established. However, establishment of an IVIVC has been possible 
so far only for certain categories of oral drug products [136]. For this, different USP dissolution 
methods are being used, which mimic reasonably well the in vivo situation in the gastrointestinal 
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tract. An IVIVC for inhalation products has however not yet been established due to the many 
challenges the method establishment entails. A clinical bridging study is usually necessary to 
compare the safety and efficacy the products that wish to claim bioequivalence [137]. One of the 
crucial missing tools is the dissolution rate assessment possibility although it has been of 
researchers’ as well as authorities’ interest for many years now [15,16,46,138]. Yet up to now, 
there is no official pharmacopoeial dissolution method for inhalation products due to the many 
difficulties faced with the in vitro method establishment (chapter 2.4.2). 
Another aspect of the IVIVC is also the response against which is the in vitro data correlated. This 
is often done against the drug’s pharmacokinetic parameters such as the concentration or area 
under curve [139]. These can be obtained from clinical, safety, efficacy, or toxicological studies, 
which are conducted on humans and/or animals during the drug product development. Yet it is 
debatable how relevant are the plasma levels for locally acting drugs. The measured drug levels 
might have only very limited validity in terms of the therapeutic effect caused by the drug. 
Therefore the in vitro data might rather be correlated with a quantifiable effect that the drug has 
(e.g. forced expiratory volume in one second). However, precious resources are used in the 
studies and in case of the animal studies, the study subjects usually have to be sacrificed. For 
ethical reasons, the animal studies should then be limited to as few as possible and in vitro assays 
should be leveraged on more frequently [40]. For this, it is desirable that the models and 
techniques applied can provide results that are representative of those that would be obtained 
from in vivo or ex vivo studies. Also computational fluid dynamics is starting to greatly contribute 
to better understanding the complex lung system especially in terms of deposition but also this 
system still need an in vivo validation [140]. 
2.4.1 Aerodynamic evaluation 
Pharmacopoeias require that all products intended for pulmonary delivery are assessed for 
delivered dose uniformity and aerodynamic particle size distribution [135]. For the former, for 
example a dosage unit sampling apparatus can be used, while for the latter it is mainly the 
impactors. An impactor is a device that classifies particles or droplets of a formulation according 
to their aerodynamic particle size (Figure 2.13). The European Pharmacopoeia lists four devices 
capable of such classification, namely the glass impinger, the multi-stage liquid impinger, the 
Andersen cascade impactor, and the next generation impactor [141]. 




Figure 2.13 Next generation impactor (NGI) with indication of the cut off diameters at 68 L/min. Adapted based on 
[142]. 
These tools are indispensable in pulmonary formulation development as they characterize the 
formulation’s aerodynamic properties by its classification according to aerodynamic particle size. 
Deposition mechanism employed during the classification is inertial impaction (discussed shortly 
in chapter 2.1.2.2) and its principle is schematically shown in Figure 2.14. The NGI body consist 
of eight sets of nozzles and impaction cups. As the air is drawn through the NGI, the number of 
nozzles gradually increases from one nozzle in stage 1, to 52 nozzles (stage 4), and eventually to 
4032 nozzles in stage 8. At the same time, the nozzles’ diameters decrease and thus the air 
velocity passing through the nozzles increases. 




Figure 2.14 Configuration of interstage passage (top) [141] and the principle of classification by impaction (below) [4]. 
During the experiment, aerosol particles are aerosolised and carried by an air stream from the 
inhaler through the body of the impactor from stage 1 to stage 8. Due to the impactor’s geometry, 
the streamlines suddenly change direction at almost right angle several times. Particles with too 
large inertia are unable to follow the streamlines, follow their trajectory and deposit on the 
impaction cup plate. Particles that follow the streamlines continue to the next stage at higher 
velocity and in the next stage same scenario occurs however at lower cut off diameter. The 
impaction and therefore also the collection efficiency is governed by the Stokes number (eq. 
(2.16), which is defined as “the ratio of particle’s stopping distance at the average nozzle exit 






where 𝜌 is the particle density, 𝑑 is the particle diameter, 𝐶  𝑖s the Cunningham correction 
factor, and 𝜂 is the dynamic viscosity [4]. 
For evaluation of the aerodynamic performance, the so called fine particle mass (FPM) or fine 
particle fraction (FPF) are calculated. The FPM or FPF are the mass or ratio of the drug amount 
below the aerodynamic particle size of 5 µm, respectively. In case of FPF, the ratio can be related 
to the expected drug amount in the formulation (declared content) or drug amount recovered in 
the impactor components (delivered content). From the impaction measurement can be also 
calculated the mass median aerodynamic diameter, which is the aerodynamic diameter below 
which falls 50% of the drug amount [143]. 
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2.4.2 In vitro dissolution testing of DPI formulations 
As it was already mentioned, there have been several attempts to create suitable in vitro 
dissolution test setup for inhaled products [144]. Among the tests employed so far are modified 
versions of the paddle (USP2)/paddle-over-disk (USP5) apparatuses [145–147], flow-through 
cell apparatus [146,148], and diffusion-controlled systems, such as the Transwell insert [149–
151] or the Franz cell [146]. However, great variability exists among the methods used, mainly in 
terms of dissolution media volume. In general, the methods might be split into two groups: one 
for which large media volumes are required (ranging between 100 mL and 1000 mL), usually 
given by size of the test equipment [152,153], and a second group where small volumes (< 5 mL) 
are sufficient. Little bit more unity exists in terms of dissolution medium: predominantly PBS at 
pH 7.4, with and without surfactants, was the dissolution medium of choice in both groups. This 
medium offers a good buffering capacity compared to the complex simulated lung fluids [147]. In 
the majority of cases, the tested powders were separated from the bulk liquid by a membrane 
forming a barrier between the particles and the liquid. Several polymeric membrane materials 
have been used, with polycarbonate being the most employed one [18]. The tested powders were 
often collected from an impactor, however either only from one impactor stage or only powder 
below certain aerodynamic size (e.g. 5 µm). Rarely have particles from more than one impactor 
stage been compared though it could be expected that due to the different geometric particle size 
these particles possess their dissolution behaviour might vary. 
In a study comparing the different methods, May and co-workers [146] reported that the 
modified UPS2 paddle apparatus showed optimal reproducibility with the best discrimination 
power. On the other hand, the Transwell setup use has been advocated due to use of low liquid 
volumes as this resembles more closely the in vivo fluid volume. Yet, it does not mimic the 
absorption-induced concentration gradients and exchange of fluids that occur in vivo [18]. Also 
the need for surfactants in the small-volume receiver compartment introduces a degree of 
arbitrariness. The concentration gradient experienced in vivo might be mimicked better by having 
a compartment with low liquid volume where the drug dissolves and then permeates to a larger, 
sink-conditions maintaining compartment. Such setup has only recently been proposed, namely 
with the Inhalation Sciences’ proprietary DissolvIt® module [154]. However, its usage in a 
standard laboratory setting is due to the proprietary nature of this system close to impossible. 
2.4.3 In vitro ADME testing 
In vitro tests are often very useful but they have a clear disadvantage of missing any input that 
could be gained from an interaction with a biological system. Without a clearly established IVIVC 
or a conducted clinical test, it is very difficult to judge on the permeability or metabolism, let alone 
the bioavailability of a drug upon its deposition. To shed light on drug’s bioavailability, which is 
affected on the one hand by its dissolution, but on the other hand also by it absorption, 
distribution, metabolism, and excretion (ADME), experience with living cells (primary or 
immortalised cell lines) is often desirable [139]. Aside from a direct clinical experience and 
animal models, testing of the interactions of particles with lung cells is usually done on ex vivo 
models, mainly on the isolated perfused lungs [30]. The ultimate goal of many researchers is to 
develop model system with in vitro cell cultures to avoid the unnecessary, ethically problematic, 
and expensive animal or human testing. A great step ahead in this direction with a significant 
potential presents the lung-on-a-chip microfluidic device, which has the first time emerged 
around ten years ago and that is being used for disease modelling, drug development, or 
toxicological studies [24,155]. Though due to its complexity it is not a commonly used tool. 
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Indtead, pulmonary cells cultures are used by researchers to study and possibly also to predict 
the fate (e.g. ADME, dissolution) and toxicological effects of drug particles once they land on the 
lung surface. As stated earlier, the composition of the lungs varies with the increasing generation 
number. Therefore, also the cell culture models used for testing should reflect the region in which 
particles are expected to deposit. There are in vitro models for tracheobronchial as well as 
alveolar epithelium, with each of this group having the possibility to use primary cell cultures or 
immortalised cell lines. 
2.4.3.1 Tracheobronchial cell cultures 
The tracheobronchial primary cell cultures can be obtained from different species (mouse, 
hamster, rat, dog, pig, cow, human, etc.) [28]. Though the primary cells generally provide the best 
correlation to the real in vivo conditions, especially the human primary cell are very difficult to 
obtain in amounts sufficient for more comprehensive studies. For drug absorption studies, the 
primary cell cultures are unfortunately suitable only for couple of subcultures. Afterwards, they 
lose the ability to form tight junctions [28]. Generally, primary cultures areless convenient and 
economical than the immortalised cell lines. Aside from the reduced costs, the use of the cell lines 
is advantageous because of their lower variability. Most commonly used are the Calu-3 and the 
16HBE14o- cell lines. Calu-3 is an adenocarcinoma cell line used mainly for permeation studies 
and employed for the investigation of metabolic processes, and was used also in a number of 
particle-cell interaction studies [156]. This cell line grows in monolayers, forms ciliated and 
secretory phenotypes but the cilia are highly irregular. It also produces a mucus layer when 
grown at ALI. 
2.4.3.2 Alveolar  cell cultures 
Primary cultures of alveolar epithelium are usually isolated from animals such as mouse, rat, 
rabbit, and pig, and from humans undergoing lung resection surgeries. They are used for most 
studies of alveolar functions like solute transport and metabolism because the cell lines do not 
form as good tight junctions. In human alveolar epithelial cells (hAEpC) was also observed the 
presence of caveolin-1 and thus they may be beneficial for study of the caveolae-facilitated 
transport of macromolecules [14]. Unfortunately, the alveolar epithelial cells exhibit very limited 
proliferation profile and are not suitable for passaging. The most frequently used alveolar cell line 
is the A549. It is a cell line of adenocarcinomic human alveolar basal epithelial cells. This cell line 
has some important biological properties of alveolar epithelial type II cells such as the surfactant 
secretion when grown on air-liquid interface [30]. It is thus widely used as an in vitro model for a 
type II pulmonary epithelial cell model. Its primary use is for toxicity studies as it shows only a 
limited ability to generate functional tight junctions, although it stains positively for zonula 
occludens-3, occludin, and claudin-2 [22]. 
2.4.3.3 Use of cell cultures for DPI formulation assessment 
Cell cultures are mostly used under submerged conditions, which is a suitable approach for most 
drug delivery routes. However, pulmonary drug delivery presents a challenge as the submerged 
conditions do not properly reflect the in vivo system where ALI exists. A thin surfactant layer on 
top of the cells can be achieved when using for example the A549 cells. The surfactant forms when 
the cells are exposed to air for at least 5h [22]. Mimicking the in vivo situation in terms of liquid 
amount and composition in the cell culture system is crucial when studying the interaction of 
deposited particles or droplets with the lung epithelium [46,157]. Even better might be the use 
of a 3D co-culture model consisting of epithelial cells (A549 or 16HBE14o-), alveolar 
Theoretical background | Characterization of inhalation powders 
32 
 
macrophages, and dendritic cells. In fact, in vivo the cells continuously cross-talk through 
intercellular signalling to maintain homeostasis and to coordinate immune responses [158]. Thus 
such am in vitro model resembles very closely the in vivo situation [30]. 
Studies that combine aerodynamically classified deposition and cell interaction are still rather 
rare. In some reports, pharmacopoeial instruments such as the twin-stage impinger [159,160], 
multistage liquid impinger [161,162], and Andersen cascade impactor [163,164] were 
transformed to accommodate a cell culture system. In one instance, also the NGI was used but 
without any description of the NGI transformation [165]. It is important to note that deposition 
in all these systems is based on impaction, which might induce certain cell stress [53]. More gentle 
deposition, however without aerodynamic classification, can be ensured using sedimentation-
based systems, e.g., the Pharmaceutical Aerosol Deposition Device on Cell Culture (PADDOCC) 
[166], Air-Liquid Interface Cell Exposure (ALICE) [167], or LTC-C Computer-Controlled Long-
Term Cultivation (CULTEX®) system [168]. Alternatively, insufflators such as MicroSprayer IA-1C 
could also be utilized for bulk powder deposition [22,169]. In the above-mentioned experiments 
where deposition was combined with cell interaction, immortalised, bronchial Calu-3 cell line 
were most commonly used. These are thus mostly relevant for study of the particle fate in the 








3 Production of fast-dissolving low-density 
powders for improved lung deposition by 
spray drying of a nanosuspension 
3.1 Summary 
We combined high-energy wet media milling and spray drying to engineer dry powders for 
inhalation consisting of geometrically large, low-density particles with superior aerodynamic 
properties and fast dissolution. Péclet number proved to be a useful instrument to guide choice 
of the additives and process conditions for generating low-density powders by spray drying. 
Composite dry powders consisted of milled and stabilized budesonide nanoparticles, leucine or 
albumin as matrix formers, and ammonium carbonate as a pore former. Powders of different 
composition showed fairly large and comparable geometric particle sizes (de,50 > 4.4 µm) with 
effective densities strongly depending on the present matrix former. Powders with lowest density 
reached an aerosol performance of up to 60%, which is well above most commercial, carrier-
based products. It was also demonstrated that the nanomilling step was indispensable to yield 
such good aerosol performance. Dissolution of aerodynamically classified particle fractions 
showed a very fast onset and was largely completed within 30 minutes irrespective of the 
formulation and the impactor stage. Mathematical kinetic modelling was used to deduce the API 
dissolution rate coefficient from the results obtained using a modified USP 2 apparatus. 
Dissolution rate was found to be determined by the properties of the API nanoparticles rather 
than those of the composite particles. The employment of industrially established, solely water-
based processes allows introducing the presented approach as a platform technology for the 
development of well-performing pulmonary formulations. 
3.2 Introduction 
For many years, pulmonary drug delivery has been an established route of administration for 
drugs that tackle lung diseases (e.g. asthma, cystic fibrosis, COPD) and has recently become 
interesting for drugs of indications unrelated to lungs, such as diabetes or pain management; 
additionally it is explored for administration of vaccines and gene therapy [54]. The majority of 
the marketed dry powders for inhalation (DPIs) formulations are based on the conventional 
approach where the drug particles cover the surface of a much larger (median particle size 
≈ 100 µm) carrier, usually lactose. 
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Although well-established, this system has several disadvantages such as poor control over the 
formulation performance, different drug delivery efficiency if formulated as mono compound or 
in combination with other drug(s), performance dependence on the inhalation flow rate, lack of 
high drug load possibility, and rather low fraction of drug delivered to the lungs (≈ 10-30%) 
[92,170]. These drawbacks can be overcome by using a particle engineering, carrier-free 
formulation approach. The use of industrially established and well-scalable manufacturing 
processes, such as spray drying, alone or in combination with other process(es), is important if 
such formulation approach should be applied in industrial setting. 
Particle engineering via spray drying uses the understanding of particle formation process for 
production of structured microparticles. In spray drying, the droplet evaporation and particle 
formation kinetics are governed by coupled heat and mass exchange processes. The drying 
process can be described by the dimensionless Péclet number (Pe, eq.3.1), which compares the 
rate of droplet surface reduction (i.e. evaporation rate κ) to the diffusion of the solutes in the 




  (3.1) 
 
As the solvent evaporates and the droplet shrinks, the solute concentration close to the droplet 
surface increases. The result of the drying, however, depends on the Péclet number: 
a) Drying at low Péclet number (Pe < 1) occurs when the evaporation in terms of surface 
area reduction is slower compared to the diffusion of the solutes. The solutes, therefore, 
diffuse along the concentration gradient from the surface towards the inside of the droplet 
provided that they do not reach saturation solubility and precipitate. Thus, solid particles 
with density close to the solute’s true density are likely to form. 
b) If the evaporation is faster than the diffusion of the solutes, i.e. for Pe larger than 1, the 
solutes reach a higher concentration close to the droplet’s surface and will, therefore, 
precipitate when they reach saturation solubility and create a shell. Consequently, density 
of such particles is smaller than the true density. Also spray drying of suspended 
(nano)particles follows a similar path because the suspended material can be considered 
immobile compared to the receding droplet surface [8]. When producing low-density 
particles at high Pe, one can use either a high molecular weight solute, which intrinsically 
has a small diffusion coefficient, or a solute that precipitates quickly in the drying process 
due to its low solubility and becomes immobile. 
Applying particle engineering in spray drying allows tailoring both the geometric diameter as 
well as particle density. The former can be tailored mostly by controlling the droplet size and, to 
lower extent, by the feed solution concentration, while the latter can be lowered by choice of 
drying conditions and formulation properties that support drying at high Pe [8]. The possibility 
to control particle production can be very beneficial for tailored manufacturing of DPIs since both 
geometric size and particle density greatly influence the aerodynamic particle size and thus the 
product performance. Furthermore, particle engineering can be advantageously used for 
production of so-called large porous particles (LPP), which have large geometric size but reach 
desirable aerodynamic size for lung deposition thanks to low density [6]. 
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Particle engineering by spray drying has been successfully utilized numerous times using many 
different drugs [102–107]. Excipients such as phospholipids (e.g. distearoyl phosphatidylcholine, 
dipalmitoyl phosphatidylcholine (DPPC), lecithin), other lipids such as cholesterol, or amino acids 
(e.g. leucine, glycine) were often employed as well as various solvents (e.g. ethanol, methanol 
isopropanol, dichloromethane). LPPs have been mostly produced by spray drying of a double 
emulsion with various excipients as matrix formers (e.g. poly(lactic-co-glycolic) acid, 
cyclodextrins, or DPPC in combination with hyaluronic acid or other excipients) [110,172]. Most 
often, the drug in such formulations was either dissolved in water or any of the co-solvents, or 
used as drug suspension. Less frequently have the drugs, especially poorly water-soluble ones, 
been pre-processed to nano range sizes [82]. 
Drug nanoparticles (NPs) have gained importance in pharmaceutical research and industry in the 
recent years, as seen e.g. by 14 wet media milled drug products for oral and parenteral use on the 
market [73]. Wet media milling (WMM) represents one of the commonly used top-down 
approaches for NP production. These possess unique properties such as higher saturation 
solubility and larger specific surface area and thus have improved dissolution kinetics [173]. 
During the milling process, the drug is ground by shear and compression forces between the 
grinding media, which is given kinetic energy from a rotating shaft and stirring elements. This 
specific energy input (Em,P) of the process is proportional to the number of milling stress events 
and their energy, which are affected by the milling time and the grinding media’s amount, density, 
size, and relative velocity [79]. The information on the specific energy input is therefore crucial 
for the outcome of the process, experiment repeatability, and process scale up. 
Nanosuspensions have the potential to provide high drug load as they can contain as little as 10% 
of stabilizer [77]. Stabilizers are needed during WMM to prevent particle growth due to an 
increase of the surface area and free Gibbs energy achieved by milling. This makes the 
nanocrystals thermodynamically unstable causing Ostwald ripening or particle agglomeration 
(Van Eerdenbrugh et al., 2008). Typical stabilizers are, e.g., Poloxamer 188 and 407, Polysorbate 
80, D-α-tocopherol polyethylene glycol 1000 succinate (TPGS), cellulosics, polyvinylalcohol, or 
sodium dodecylsulphate [78]. 
Numerous poorly water-soluble drugs have been nanomilled in the last 15 years [80] with 
median particle sizes ranging from < 100 nm [81] to ≈ 650 nm [82], or even larger in screening 
studies [83]. Unfortunately, only few studies [85–87,174] related the obtained nanoparticle sizes 
to the Em,P. 
Only few studies have combined the WMM using a traditional equipment and spray drying for 
production of DPIs; their focus was rather on milling parameters (e.g. use of co-milling agent, 
exploration of different stabilizers) and the influence of drug substance properties [82,111,175]. 
Dissolution is a prerequisite for bioavailability [16] and can be challenging to bigger or lesser 
extent for a poorly water-soluble drug, depending on its solubility in the given biological fluid. 
Drug particles delivered to the lungs encounter several obstacles on their way from solid to 
dissolved state, including mucociliary clearance and alveolar phagocytosis. Therefore, for a drug 
to be effective it is important that it dissolves before it is cleared. 
It is common to predict the in vivo release kinetics of oral dosage forms using data obtained from 
in vitro dissolution tests that employ various pharmacopoeial methods [176]. For inhaled 
products, however, there is still no pharmacopoeial technique that would allow confident 
assessing of the dissolution characteristics. There have been several attempts to create suitable 
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setups for in vitro dissolution tests of inhaled products [144]. Most common tests used are 
modified versions of the paddle/paddle-over-disk apparatus [146,147,177], flow-through cell 
apparatus [146,148], and diffusion-controlled systems, such as the Transwell insert [149–151] 
or the Franz cell [146]. However, great variability exists among the methods employed, mainly in 
terms of dissolution media volume. The methods might be split into two groups: one for which 
large media volumes are required (ranging between 100 mL and 1000 mL), usually given by size 
of the test equipment [152,153], and a second group where small volumes (< 5 mL) are sufficient. 
Predominantly PBS at pH 7.4, with and without surfactants, was the dissolution medium of choice 
in both groups likely due to its good buffering capacity instead of the simulated lung fluid. In the 
majority of cases, the tested powders were separated from the bulk liquid by a membrane 
forming a barrier between the particles and the liquid. Several polymeric membrane materials 
have been used, with polycarbonate being the most employed one [18]. 
Usually, the tested powders were collected from an impactor, either from one impactor stage or 
powder below certain aerodynamic size (e.g. 5 µm). Only rarely have particles from more than 
one impactor stage been compared. 
In a study comparing the different methods, May et al. [146]reported that the modified paddle 
apparatus showed optimal reproducibility with the best discrimination power. On the other hand, 
the Transwell setup use has been advocated due to use of low liquid volumes as this resembles 
more closely the in vivo fluid volume; however, it does not mimic the absorption-induced 
concentration gradients and exchange of fluids that occur in vivo [18], and the need for surfactants 
in the small volume receiver compartment introduces a degree of arbitrariness. The 
concentration gradient experienced in vivo might be mimicked better by having a compartment 
with low liquid volume where the drug dissolves and then permeates to a larger, sink-conditions 
maintaining compartment. Such setup has only recently been proposed, namely with the 
Inhalation Sciences’ proprietary DissolvIt®  module [154]. 
The objective of this work was to develop and manufacture formulations of low-density 
composite particles for pulmonary delivery using the combination of high-energy wet media mill 
for nanoparticle production with spray drying for particle engineering in order to harness the 
advantages of both processes. Spray drying at high Pe guided the choice of formulation 
composition and process parameters with the aim to obtain engineered powders exhibiting fast 
dissolution, maximal fine particle fraction for deep lung deposition, and maximal geometric size. 
This work involves industrially established processes to ultimately introduce this as platform 
technology for pulmonary formulation development. To the best of the authors’ knowledge, this 
approach has not been proposed in the context of optimizing inhalation drug product 
performance before. Budesonide was used as a model drug substance and the obtained results 
were compared with a commercial product. Mathematical kinetic modelling was employed to 
deduce the dissolution rate of the API contained in the powders that were collected at different 
stages of the new generation impactor (NGI) from results obtained using a modified USP 2 
apparatus. 
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3.3 Materials and methods 
3.3.1 Materials 
Budesonide and D-α-tocopherol polyethylene glycol 1000 succinate (TPGS) were purchased from 
Atomole Scientific (Wuhan, China). L-leucine (Leu), ammonium bicarbonate (AC), bovine serum 
albumin (Alb), sodium diphosphate dibasic, potassium phosphate monobasic, and sodium 
chloride were obtained from Sigma-Aldrich (Buchs, Switzerland). Ammonium formate, formic 
acid, and phosphoric acid were from Fluka (Switzerland). Ethanol and acetonitrile (both HPLC 
grade) were purchased from J.T.Baker (Deventer, The Netherlands). Ultrapure water (Milli-Q, 
Millipore) was used for all experiments. Budesonide was chosen as a model drug as it is poorly 
soluble in water and it is used as an inhalation therapy for asthma. All raw materials were used 
as received. 
3.3.2 Methods 
3.3.2.1 Preparation of budesonide nanosuspensions 
First, budesonide (5% w/v) was dispersed in 800 mL of water containing TPGS at a concentration 
of 1.25% (w/v), and the suspension was stirred overnight using a propeller stirrer. Subsequently, 
the suspension was milled in wet media mill DYNO®-MILL MULTI LAB (Willy A. Bachofen 
Maschinenfabrik, Muttenz, Switzerland), equipped with a 561 mL net volume grinding chamber, 
at a suspension feed rate of 1 L/min. The stirrer tip speed applied was 12 m/s. Yttrium-stabilized 
zirconia (SiLibeads Type ZY Premium) with bead size 0.15 - 0.25 mm (Sigmund-Lindner 
(Warmensteinach, Germany)) was used as milling media at filling ratio of 60%. The resulting 
nanosuspension was sampled at 30, 60, 90, 120, 150, and 180 min. The particle size of the 
nanosuspension was analysed using photon correlation spectroscopy (cf. Chapter 2.2.3 Particle 
size determination). For characterization by X-ray diffraction, a droplet of nanosuspension was 
air dried on the specimen holder and measured without further preparation using a D2 Phaser 
diffractometer by Bruker AXS, (Karlsruhe, Germany).  
3.3.2.2 Spray drying  
Prior to spray drying, the nanosuspension was diluted to 300 mL with purified water generated 
by MilliQ system to reach a final active pharmaceutical ingredient (API) concentration of 0.5% 
(w/v). Leucine or albumin was added to the nanosuspension as matrix former to achieve final 
total solids concentration of 1% (w/v). Ammonium carbonate was added to some feedstocks at 
concentration of 2% (w/v) and it was expected to completely evaporate during drying. For 
comparison, a suspension of not milled budesonide containing the spray drying additives was 
also spray dried. Finally, a formulation of nanosuspension without any additives with a final API 
concentration of 1% (w/v) was prepared. Table 3.1 gives an overview of the formulations.  
The feedstock was spray dried in a Mini Spray Dryer B-290 coupled with Dehumidifier B-296 and 
molecular sieve (all Büchi Labortechnik, Flawil, Switzerland) using a 0.7 mm two-fluid nozzle that 
was cleaned pneumatically every 30 seconds, with nitrogen as the spraying gas. For the 
manufacture of the different formulations, the inlet temperature, the feedstock flow rate, the 
atomizing pressure setting, and the aspirator flow rate were kept at 170°C, 9 mL/min, 35 mm, 
and 35 m3/h, respectively. A yield of 70-80% was achieved. Initial experiments were performed 
to define these spray drying conditions. In these, the effect of the inlet temperature 
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(170°C/200°C), the atomizing pressure setting (35 mm through 55 mm), and the feedstock 
concentration (0.1%, 1%, and 4% (w/v)) on median geometric particle size and aerosol 
performance were studied. The outlet temperature depended on the inlet temperature and was 
around 63°C and 83°C for inlet temperatures of 170°C and 200°C, respectively. The humidity of 
the drying gas was kept below 5% during all experiments. The spray-dried powders were stored 
for one week at a temperature of 22 ± 2°C and relative humidity 50 ± 5% before characterization.  
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3.3.2.3 Particle size determination 
Photon correlation spectroscopy (PCS) 
The particle size of the nanomilled suspension was measured by photon correlation spectroscopy 
using a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, United Kingdom) at a 
wavelength of 633 nm at 25 °C. 
Laser diffraction (LD) 
Laser diffraction (LD) was used to determine the particle size of the spray-dried powders. The 
instrument consisted of a HELOS sensor and the dispersing system RODOS, equipped with the 
micro dosing unit ASPIROS (all Sympatec (Clausthal-Zellerfeld, Germany)). The software Windox 
5 (Sympatec, Switzerland) was used to evaluate the measured data. Approximately 150 mg of the 
powder was filled in a glass vial. Each spray-dried sample was measured in triplicate in the 
measurement range of 0.1/ 0.18 to 35 μm. All measurements were done at primary injector 
pressure of 1 bar. 
3.3.2.4 Scanning electron microscopy (SEM) 
Particle size and morphology of the spray-dried powders were determined with a Zeiss Supra VP 
40 scanning electron microscope (SEM; Carl Zeiss, Jena, Germany). Prior to imaging, the samples 
were sputter-coated with gold for 45 s using a Polaron SC 7620 (ThermoVG Scientific, United 
Kingdom). The pictures were taken under high vacuum at a voltage of 5 kV and a working distance 
of 5 mm. 
3.3.2.5 Specific surface area 
The specific surface area was measured by gas adsorption using the BET method. For this, the 
surface area analyzer Gemini-2360 (Micrometrics, USA) was used. Powder samples were flushed 
overnight with helium and measured in triplicate using nitrogen in relative pressure range 0.05–
0.25 (p/p0). 
3.3.2.6 Mercury porosimetry 
Micromeritics AutoPore IV 9500 system at maximum pressure of 212 MPa (corresponds to 
ca. 31000 psia) was used to measure the pore volume within the particles and to calculate the 
effective density of the particles. The effective density 𝜌 was calculated using equation: 
𝜌 = 𝜌 1 −
𝑉
𝑉
  (3.2) 
Where, ρ is true density, 𝑉  is the volume of pores below 5 µm, and 𝑉  is the total volume 
of the particles, i.e. the volume of the pores and the solid combined. Prior to loading into the 
measurement cell, the powder was slightly compressed to create a defined object to be analysed. 
3.3.2.7 Aerodynamic performance 
The Next Generation Impactor (NGI; Copley Scientific, United Kingdom) was used to determine 
the aerodynamic performance of the spray dried powders. Approximately 1 mg of the powder 
was manually filled into a two-piece hypromellose capsule of size 3 (gifted from CAPSUGEL®, 
France). The capsule was placed in a monodose dry powder inhaler (type RS01 Mod. 8, kindly 
donated by Plastiape S.p.a., Italy) and the powder was lead through the impactor for 3.5 s at an 
airflow that generated a 4 kPa pressure drop, namely 68 L/min. Prior to each measurement, the 
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collection cups were coated with a 1% (w/v) glycerol in ethanol (EtOH) solution. The deposited 
powders were recovered by ethanol extraction using an orbital shaker for 30 minutes; stages 1 
and 8 were extracted due to their larger size using 25 mL of ethanol, while stages 2-7 were each 
extracted with 10 mL EtOH. The budesonide content of each of these ethanolic solutions was 
quantified using the above-mentioned  HPLC-MS method.  
The fine particle fraction (FPF) was calculated as the fraction of total budesonide amount 
recovered in particles with an aerodynamic diameter < 5 µm by interpolation within stage 2. 
3.3.2.8 High-performance liquid chromatography/Mass spectrometry (HPLC-MS) 
An HPLC-MS system consisting of a degasser G1379B, binary pump G1312A, autosampler 
G1367B, thermostat G1330B, column oven G1316A (series 1100), and a quadrupole MS detector 
G6130A (all Agilent Technologies, USA) was used to quantify budesonide content. A Kromasil C8 
reversed phase column (100 x 2.1 mm, 5 μm (Phenomenex®, USA)) was used. The mobile phase 
consisted of 25 mM ammonium formate buffer (pH 3.2) and acetonitrile in ratio 1:1 and was used 
at flow rate of 0.2 mL/min. Sample injection volume of 50 µL was employed. 
The ions were generated by atmospheric pressure electrospray ionization. MS detector was 
operated at positive polarity with fragmentor set to 100 V, capillary voltage 4000 V, drying gas 
flow 10 L/min, drying gas temperature 350°C, and nebulizer pressure 20 psig. Budesonide was 
detected in SIM mode as [M+H]+ at m/z 431. 
3.3.2.9 Dissolution testing 
The technique for dissolution testing was based on that developed by Son et al. [147]. The 
powders from NGI stages 3, 4, and 5 (cutoff diameters 4.16, 2.64, and 1.56 µm, respectively) were 
taken for the dissolution tests using modified NGI collection cups (Copley Scientific, UK). This 
allowed small dose of aerodynamically classified powder to be tested. After powder deposition 
and insert removal from the impaction cup, 200 µL of dissolution medium were placed on the 
insert’s surface near the powder and a polycarbonate membrane (pore size 0.05 μm, thickness 
6 μm (Whatman Nuclepore™, USA)) was fixed on top of the powder. Such insert was placed as 
quickly as possible into a cylindrical dissolution vessel, which was subsequently filled with 
300 mL of dissolution medium consisting of phosphate buffered saline (pH 7.4). The dissolution 
test, therefore, resembled the USP Apparatus 5 (paddle over disk) test setup (Figure 3.1). The 
dissolution was tested at 37.0 ± 0.5°C using the paddle stirrers at 50 rpm. Samples of 2 mL were 
taken from the 300 mL bulk solution after 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 180, 240, 360, 
480, and 1440 minutes. The sample volume was immediately replenished with new dissolution 
medium. At the end of the dissolution experiment, the membrane was cut open using a scalpel to 
allow dissolution of any undissolved powder in the bulk solution. Prior to analysis, all samples 
were centrifuged at 16100 × g for 10 minutes. 
In addition to measuring the dissolution with powders deposited on different NGI stages, 
dissolution experiments using the complete (i.e. not aerodynamically classified) formulations 
were carried out. In these experiments, an exactly weighed amount of approximately 1 mg of each 
formulation was placed on the impaction insert and the test was subsequently performed in an 
identical fashion as for the NGI stages. Additionally, physical mixture (PM) of budesonide and 
leucine in ratio 1:1, prepared by low shear mixing, was tested. 
The TPGS concentration in the 200 µL of dissolution medium was evaluated for each formulation 
based on the recovered drug amount and the nominal drug and stabilizer content of the powders 
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and compared to the critical micellar concentration of TPGS. Additionally, the solubility of the 
drug in the dissolution medium was evaluated by adding drug in excess into dissolution medium, 
stirring for at least 24 hours, centrifuging and determining drug concentration in the supernatant. 
 
Figure 3.1 Dissolution test setup. 
3.3.2.9.1 Kinetic model for the estimation of dissolution coefficient 
In the dissolution setup used, inner and outer compartments were formed within the vessel. The 
dissolution took place in the inner compartment while the drug was quantified in the outer 
compartment after permeating through the membrane. 
To estimate the dissolution coefficient of budesonide, a kinetic model was developed. The 
dissolution rate of a solid substance in a liquid medium is described by the classical Noyes-






(𝐶 − 𝐶)  (3.3) 
where, m is dissolved drug amount, t is time, D is diffusion coefficient, S is surface area of solid 
substance, h is thickness of diffusion boundary layer, Cs is saturation solubility of drug in the 
medium, and C is concentration of dissolved drug substance in the medium. 





where, mp is mass of the drug substance particles,  is shape factor accounting for particles’ 
surface area deviation from that of a sphere, ρ is particle density, and dg is geometric particle 
diameter. 
By introducing Eq. (3.4) into Eq. (3.3) and considering that particle mass and particle diameter 




𝐷 6  𝑚 (0) −  𝑚  
ℎ 𝜌 𝑑 (0) 𝑚 (0) −  𝑚 𝑚 (0) 
(𝐶 − 𝐶) (3.5) 
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where, mp(0) is initial drug particle mass and dg(0) is initial geometric diameter of the particles. 





𝑞 𝐷 6  𝑚 (0) − 𝑚
ℎ 𝜌 𝑑 (0) 𝑚 (0) − 𝑚 𝑚 (0)
(𝐶 − 𝐶) (3.6) 
where, 1/q is the mass fraction of drug substance in the particle and mp(0) is in this case the initial 
amount of drug substance contained in the particles, and dg(0) is initial geometric diameter of 
particles. 
If, on the other hand, the total initial mass of particles rather than their drug substance content is 




𝐷 6  𝑚 (0) − 𝑞 𝑚
ℎ 𝜌 𝑑 (0) 𝑚 (0) − 𝑞 𝑚 𝑚 (0)
(𝐶 − 𝐶) (3.7) 
where, mp(0) in this case represents the initial total mass of the particles consisting of drug 
substance and excipients. 






𝑚 (0)(𝑖) − 𝑞 𝑚(𝑖)
𝑑 (0)(𝑖) 𝑚 (0)(𝑖) − 𝑞 𝑚(𝑖) 𝑚 (0)(𝑖)
(𝐶 − 𝐶) (3.8) 
where, i denotes size fraction and n varied in this work between 24 and 27 depending on the 
formulation under investigation. 
In the employed experimental arrangement, the studied drug formulation was contained in the 
inner compartment that was separated from the outer bulk solution of the vessel by a polymeric 
membrane (Figure 3.1). The rate of change of concentration, C, of dissolved drug substance in the 








− 𝐴  𝑃 (𝐶 − 𝐶 ) 𝑉⁄  (3.9) 
where, Am is surface area of the membrane, P is permeability coefficient of the membrane for the 
drug substance, V is volume of the inner compartment, and Cb is drug substance concentration in 
the bulk solution of the vessel. 
Finally, the rate of concentration change in the bulk solution is expressed by: 
𝑑𝐶
𝑑𝑡
= 𝐴  𝑃 (𝐶 − 𝐶 ) 𝑉⁄ − ?̇? (𝑡) 𝐶 𝑉⁄  (3.10) 
where, Vb is volume of the bulk solution and ?̇? (𝑡) is the rate of volume sampling from the 
bulk solution. This was approximated by the following empirical equation that was obtained by 
fitting to the withdrawn sample volume at the successive time points: 
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?̇? (𝑡) = 0.559 − 1.17 10 𝑡 + 9.9 10 𝑡 − 3.93 10 𝑡 + 7.31 10 𝑡
− 5.13 10 𝑡  
(3.11) 
The following boundary conditions were applied: 
𝑡 = 0, 𝑚 = 0, 𝐶 = 𝐶(0), 𝐶 = 0 




0, [0, 𝑡 )
𝑎𝑠 𝑖𝑛 𝐸𝑞. (13) 𝑜𝑟 𝐸𝑞. (8), [𝑡 , ∞)
   (3.12) 




𝑞 𝐷 6  𝑚 (0) − 𝐶(0)𝑉 − 𝑚
ℎ 𝜌 𝑑 (0) 𝑚 (0) − 𝐶(0)𝑉 − 𝑚 𝑚 (0) − 𝐶(0)𝑉
(𝐶 − 𝐶)   
(3.13) 
The system of eq. (3.9), (3.10) and (3.12) with either Eq. (3.13) for the individual deposition 
stages of the NGI or eq. (3.8) for the complete formulation were fitted to the measured 
concentration values in the bulk solution by least-square regression analysis following numerical 
solution of the differential equations using the software EASY-FIT [178]. From the fit, optimal 




, 𝐶(0), 𝑃 𝑎𝑛𝑑 𝑡  
The value of q was estimated from the total dissolved drug substance amount at the end of the 
experiment with the complete formulations and the same q value was also used in the dissolution 
experiments with the NGI stages. For mp(0)(i) and dg(0)(i) in eq. (3.8) the relative volume 
distribution and the equivalent particle size de, respectively, were used, which were taken from 
the particle size distribution of the complete formulation determined by LD. For mp(0) and dg(0) 
in eq. (3.13), the total dissolved drug substance amount at the end of the experiment and the 
average aerodynamic particle size of the respective deposition stage, respectively, were used. 
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3.4.1 Characterization of raw material  
The budesonide drug particles prior to milling are shown in Figure 3.2 (left); the particles had 
cuboid shape and formed rather large agglomerates. The median particle size was 2.83 µm with 
largest particles reaching ≈ 20 µm and around 25% of particles were very fine (< 1 µm) (Figure 
3.2, right). 
 
Figure 3.2 SEM micrograph (left) and particle size distribution by LD (right) of raw budesonide. 
3.4.2 Wet media milling 
Based on a screening study [179], which tested the ability of different stabilizers such as 
polysorbate 80, poloxamer 188 and 407, and TPGS to stabilize the nanoparticulate system (data 
not shown), TPGS was chosen as the preferred stabilizer as smallest nanoparticle size and 
narrowest distribution was achieved. TPGS, a GRAS listed compound, included in NF and 
approved by the FDA for per-oral administration is used here as research reagent. WMM with this 
stabilizer was performed for 150 minutes and generated nanoparticles of median particle size 
263 ± 39 nm at specific energy input of 137 ± 3 MJ/kg.  
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Figure 3.3 Left: SEM micrograph of budesonide nanoparticles after WMM at specific energy input of 
137 MJ/kg. Right: Particle size reduction during wet media milling. 
3.4.3 Spray drying conditions 
The spray drying conditions used for production of the final powders in Table 3.1 were chosen 
based on a series of initial experiments. In these, the influence of inlet temperature and 
formulation composition (Figure 3.4), atomizing pressure (Figure 3.5), and concentration of 
feedstock (data not shown) on median geometric particle size (de,50) and FPF was studied. In 
general, the larger the geometric particle size the lower the FPF. Formulations containing 
ammonium carbonate, for instance, exhibited smaller geometric size and higher FPF than the 
ones without this excipient. As a notable exception, powders produced at 170°C with leucine had 
a larger geometric size and a higher FPF than the formulation with albumin. Also, at 200°C 
formulations with leucine and albumin exhibited a larger or the same geometric size as the 
formulation with glycine but a higher FPF. The use of higher inlet temperature led to smaller de,50 
for powders with all used additives except for albumin (Figure 3.4 left) while this larger geometric 
size was accompanied by an increase of FPF for the albumin formulation (Figure 3.4 right). 
 
Figure 3.4 Median geometric particle size (left) and FPF (right) as a function of inlet temperature of 
powders containing varying ratios of leucine (L)/ammonium carbonate (AC), albumin, leucine, or glycine 
as spray drying additives. 
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Increase of atomizing pressure, one of the main factors influencing the droplet size, had a clear 
negative effect on the median geometric particle size while it simultaneously caused an increase 
of FPF (Figure 3.5). 
 
Figure 3.5 Median geometric particle size and FPF as a function of atomizing pressure of powders 
with leucine as spray drying additive. 
Since the aim of this study was to create geometrically large particles with good aerodynamic 
performance, the following spray drying conditions were selected based on these results: 
Atomizing pressure setting of 35 mm and inlet temperature of 170°C. Based on previous 
experience, feedstock flow rate of 9 mL/min and total solids concentration (excluding AC) of 
1% w/v were chosen. The ratio of leucine to ammonium carbonate, when used in a mixture, was 
set to 50/200. 
3.4.4  Manufactured powders 
The physical properties of the 5 spray dried formulations are shown in Table 3.1. In 4 cases, the 
feedstock contained the WMM budesonide in form of a nanosuspension (NS), while in the fifth 
case budesonide was not milled and was spray dried as a suspension (S) containing the additives. 
Table 3.1  Overview of compositions of spray drying feedstocks with the resulting median geometric 












NS/ Nanosuspension - 5.30 ± 0.06 2.1 ± 0.1 0.74 
NS/Alb Nanosuspension Albumin 5.01 ± 0.10 3.5 ± 0.1 0.52 










5.04 ± 0.02 6.9 ± 0.2 0.54 
a Values represent average ± SD (n=3) 
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The median geometric particle size was similar for all formulations and ranged between 4.39 μm 
and 5.30 μm. Considerable differences were seen in the specific surface areas, formulations with 
nanosuspension and leucine as an additive yielded much higher surface area than the other 
formulations. The same formulations produced particles with the lowest effective density. The 
additives had also an influence on the shape and morphology of the particles (Figure 3.6). For 
example, powders of formulation NS/Alb crumpled during drying and formed raisin-like particles 
(Figure 3.6A) while formulations containing leucine appeared sponge-like (Figure 3.6B). 
 
Figure 3.6 SEM micrographs of spray-dried powders with albumin (A, formulation NS/Alb) and 
leucine (B, formulation NS/Leu) as spray drying additive. 
3.4.4.1 Aerodynamic properties 
The additives affected also considerably the aerodynamic particle size distribution of the 
powders (Figure 3.7). Formulation NS/Leu+AC containing nanosuspension, leucine, and AC (red 
line) showed very good aerodynamic performance, which can be judged by the high deposition 
in stages below 7.49 µm cutoff diameter and low deposition above this cut-off. On the other hand, 
formulations NS/ (green line) and S/Leu+AC (black line) had highest deposition in the induction 
port, which mimics the throat and where large particles or agglomerates deposit. The poor 
aerodynamic performance of these formulations was reflected also in the low FPF values they 
reached (Figure 3.8). 
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Figure 3.7 Aerodynamic particle size distribution of different formulations of spray-dried powders 
in the NGI with the cutoff diameters of each stage (IP = induction port, PS = pre-separator). 
Formulation NS/Leu+AC reached the highest FPF of around 61%, while the lowest FPF (around 
18%) was obtained with formulation NS/, which contained the nanomilled drug alone (Figure 
3.8). Interestingly, formulation S/Leu+AC containing also leucine and ammonium carbonate as 
additives but drug suspension rather than nanosuspension as the feedstock basis reached a 
rather low FPF of only around 22%. Between the two additives Leu and Alb, the former had a 
more positive effect on FPF. By comparison, aerodynamic performance of a commercially 
available budesonide product (Miflonide® 400 µg, Novartis AG) reached a FPF of 21%. This was 
evaluated using the Aerolizer device supplied with the packaging. Notably, formulations 
produced in this work applying the particle engineering approach outperformed the commercial 
product. 
 
Figure 3.8 Fine particle fraction of different formulations of spray-dried powders. 
The effective density measured by mercury porosimetry was lowest for formulations NS/Leu+AC 
and NS/Leu. These formulations exhibited as seen above the highest FPF. Hence, addition of 
leucine to the nanosuspension formulations is shown to aid the formation of low-density porous 
particles with smaller aerodynamic diameters than the other formulations although the 
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geometric diameter remained largely unaffected. Ammonium carbonate had a positive effect on 
FPF but not on the effective density and lowered somewhat the geometric diameter. Bulk density 
was expectedly much lower than the effective density. Interestingly, this quite more simple 
measurement produced in general a similar trend for the studied formulations as the effective 
density with the exception of S/Leu+AC (Figure 3.9). 
 
Figure 3.9 Effective (bars) and bulk (diamonds) densities of the spray-dried powders. 
3.4.4.2 Dissolution rate 
Figure 3.10 shows an example of concentration data in the bulk solution and the corresponding 
line obtained by model fitting (according to Chapter 3.3.2.9.1) for powder from stages 3 through 
5 of formulation NS/Leu+AC. We observed a very fast onset of dissolution that was largely 
completed within 30 minutes. No differences were observed among the individual NGI stages. 
Comparable results were obtained for the remaining four formulations (Appendix 8.1). 
The model fitting to the dissolution results of NGI stages 3, 4, and 5 of all formulations yielded 
values for the dissolution rate parameter kdiss shown in Figure 3.11. Significant values of initial 
concentration C(0) were deduced. These were larger for formulations NS/Alb, NS/Leu and 
NS/Leu+AC than for S/Leu+AC and the physical mixture and they decreased for the three stages 
generally in the order 3 > 4 >5. The C(0) values ranged between 0.15 and 0.2 mg/mL (in stage 3) 
and 0.05 and 0.1 mg/mL (in stage 5) for the former formulations, and between 0.05 and 
0.1 mg/mL and 0 and 0.05 mg/mL in these stages for the latter formulations. Notably, these C(0) 
values of the first group of formulations lie above drug substance solubility in the dissolution 
medium. For the permeability coefficient P, an average estimate of 1.6510-3 cm/min (standard 
error = 3.6110-4 cm/min, n = 23) was obtained. Goodness of Fit (GOF) was in all cases 
satisfactory (GOF > 0.999) [178]. 
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Figure 3.10 Example of dissolution test result of formulation NS/Leu + AC. Crosses represent the 
measured drug concentration in the bulk solution (Cb), lines represent fitted dissolution profile; (top) 
dissolution of powder from stage 3, (middle) dissolution of powder from stage 4, (bottom) dissolution of 
powder from stage 5. 
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Figure 3.11 Overview of dissolution rate parameters kdiss for deposition stages 3, 4 and 5 deduced 
by model fitting. Order of formulations from left to right corresponds to that in the legend from top to 
bottom. 
No clear difference in kdiss for the different formulations in the three NGI stages is observed 
(Figure 3.11). Also, no trend between the NGI stages can be postulated, since the value of kdiss 
appears to fluctuate with some exceptions around 10-5 cm4/(min · mg). Furthermore, the 
deduced value of P did not seem to depend on formulation or stage. 
The complete formulations exhibited by comparison a more gradual dissolution. Experimental 
data and fitted line are shown for NS/Leu+AC as typical example in Figure 3.12 (and Appendix 
8.1). The deduced parameter values by model fitting are given in Table 3.2. Only the dissolution 
parameter kdiss could be determined with certainty, while the other three adjustable parameters, 
i.e., C(0), P, and tch, had a large standard error (SE) and their confidence interval at the 5% level 
included the zero point. They were therefore assigned low priority and eliminated [178]. The 
values of q (Eqs. 6-8, 13) were estimated from the total dissolved drug substance amount at the 
end of the experiment and corresponded to a mass fraction of drug substance, 1/q, for the 
different formulations of 0.3356 to 0.3954. The GOF was in all cases better that 0.999 
underscoring the high significance of the model approximation. 
Hence, the use of parameter kdiss alone was sufficient to explain the experimental data of the 
complete formulations. Notably, fixing membrane permeability coefficient, P, to 
values < 0.01 cm/min markedly reduced the GOF while larger fixed values of P did not alter the 
goodness of the approximation or the deduced value of kdiss. For the physical mixture 
exceptionally, a fixed value of P ≈ 0.01 cm/min or larger had to be used a priori in order to obtain 
a reliable estimate of kdiss with a small SE while much smaller values for P yielded kdiss values 
whose confidence interval included the zero point and ultimately worsened the GOF. 
Table 3.2 Dissolution rate parameter kdiss in cm4/(min·mg) of complete formulation powders 
deduced by model fitting. 
NS/Alb NS/Leu NS/Leu+AC S/Leu+AC  Physical mixture 
3.18E-5 ± 3.93E-6 2.37E-5 ± 1.48E-6 2.73E-5 ± 4.45E-6 2.04E-5 ± 2.01E-6 2.06E-6 ± 2.41E-7 
a  Estimated values ± SE of estimate 
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Interestingly, no significant difference (at p = 0.05) in the dissolution parameter is found between 
the four spray dried formulations considering the error of estimate (p = 0.01 only for the pair 
NS/Alb and S/Leu+AC). The resulting kdiss values are of the same order of magnitude as the values 
deduced for the powders deposited at the different NGI stages. Solely the physical mixture yielded 
a 10-fold smaller kdiss compared to the other complete formulations, this difference being highly 
significant (p = 0.00). 
 
Figure 3.12 Example of dissolution test result of complete formulation NS/Leu + AC. Crosses 
represent the measured drug concentration in the bulk solution (Cb), lines represent fitted dissolution 
profile. 
3.5 Discussion 
3.5.1 Spray drying process conditions 
Generation of geometrically smaller particles (Figure 3.4) at higher inlet and therefore higher 
outlet temperature could be explained by fast diffusion of dissolved excipient from the surface 
towards the interior of the droplet during drying. Higher temperature results in faster solvent 
evaporation and therefore faster concentration increase of excipient at the surface. High diffusion 
coefficient excipients will be transported in larger amounts along the concentration gradient 
towards the centre before precipitating in the receding perimeter of the droplet, leading to the 
formation of particles with smaller geometric size and higher density. This likely occurs in all 
leucine-containing formulations in the used temperature values reflecting relatively small Pe 
numbers. For albumin on the other hand, a high molecular weight, low diffusion coefficient 
excipient, increased solvent evaporation rate and faster concentration rise caused by the higher 
temperature probably elicits a sooner precipitation at the perimeter resulting in larger and less 
dense particles in accordance with a large Pe number. Interestingly, leucine as an excipient gave 
geometrically larger particles than albumin at 170°C whereas the opposite was true at 200°C. 
Hence, the different Pe number of the two compounds alone does not explain their behaviour and 
additionally their different solubility and therefore time to reach saturation plays an important 
role in the particle formation process.   
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Reduced geometric diameter at higher temperature is expected to correspond to an increased 
FPF provided that the density of the particles remains roughly the same. This was not observed 
in three of the formulations with L/AC suggesting that particle density at the higher drying 
temperature was higher than at the lower temperature. Hence, the phenomena described above 
led for these formulations to the generation of particles whose density increased as their size 
decreased. The addition of ammonium carbonate that was envisaged to improve particle porosity 
upon its removal did not fulfil this intention possibly because sublimation of this additive caused 
bursts and/or breaking apart of the particles. The formulation containing only leucine and the 
formulation with the highest ammonium carbonate content seemed to have slightly improved 
FPF at the higher temperature. Notably, use of albumin as an additive produced a higher FPF that 
was accompanied by a larger geometric particle size, strongly indicating that particle density was 
reduced at the high drying temperature (Figure 3.4). At 170°C, on the other hand, the density of 
leucine-containing particles was lower than that of albumin-containing particles as both 
geometric size and FPF of the former were larger than of the latter. Thus, the response of the 
albumin-containing formulation to temperature increase is shown to be more pronounced and 
favourable from a pulmonary delivery point of view than the one of the leucine-containing 
formulation. These results demonstrate the principle invoked for particle engineering at large Pe 
numbers. 
The observed trend in Figure 3.5 of smaller de,50 with increasing atomizing pressure setting was 
expected since higher atomizing pressure leads to creation of smaller droplets and thus smaller 
particles. The simultaneous strong increase in FPF with increasing atomizing pressure setting, on 
the other hand, would suggest that the particle density was largely unaffected by the atomizing 
pressure as Pe is expected to remain almost the same with changes of atomizing pressure. 
3.5.2 Performance of manufactured powder formulations 
The geometric particle size of the powders was similar throughout all the formulations at the 
employed process conditions. Formulation NS/Leu+AC only exhibited a somewhat smaller de,50, 
which may be ascribed to bursts of the droplets and/or particles as ammonium carbonate 
sublimes, leading to the creation of smaller particles. 
Significantly, marked differences in the aerodynamic performance were evident between 
formulations. The use of leucine as an additive together with the nanosuspension in the feed 
yielded considerably higher FPF than the other formulations. Given that the variation in 
geometric particle size between formulations was rather small (Table 3.1), the difference in 
aerodynamic performance was most likely due to differences in particle density. This was 
confirmed by the effective density measurements (Table 3.1). These results demonstrate that the 
addition of leucine elicited the formation of porous particles with decreased aerodynamic particle 
size. The latter was ultimately affected by precipitation of leucine in the perimeter of the drying 
droplets. Leucine is shown to be somewhat more efficient in this respect than albumin under the 
employed process conditions (Figure 3.7 and Figure 3.8) probably on account of the shorter time 
it requires to reach saturation concentration. At a higher inlet temperature (200°C), on the other 
hand, used in the investigation of the spray drying conditions (Figure 3.4), albumin-containing 
compositions were found to improve their performance relative to their leucine counterparts 
reflecting a process at larger Pe number for albumin. Ammonium carbonate did not contribute to 
the generation of increased porosity in the particles causing instead a geometric size reduction 
possibly because of burst during sublimation. Therefore, the improved FPF of the NS/Leu+AC 
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formulation is likely related to its even smaller geometric particle size as its particle density was 
not reduced compared to NS/Leu.  
It is intriguing to note that formulation S/Leu+AC despite having the same composition as 
NS/Leu+AC exhibited a higher effective density and a much smaller FPF. This indicates that 
nanomilled API particles are necessary in order to obtain the porous composite particles 
providing enhanced aerodynamic performance. The reason for this can be that the distribution of 
the original drug microparticles within the droplets, and therefore also in the dried particles, is 
not as homogeneous as when nanosuspension feedstock is used. This could be expected due to 
the fact that the drug substance particles reach rather large sizes with de,90 of 8.4 µm (Figure 3.2). 
It is, therefore, unlikely that small composite particles will contain these large drug substance 
particles. Therefore, we assume that the particles of formulation S/Leu+AC that reach the lower 
NGI stages (stage 2 and below) contain only small drug particles, which account for ca 25% of the 
raw material particles. 
Hence, careful choice of process and formulation parameters as well as raw material 
preparation/pre-processing are required to allow particle engineering by spray drying that 
insures production of powders with optimal aerodynamic properties. It was shown that applying 
the particle engineering approach has large potential to improve the product performance 
compared to the commercial product. In addition, once deposited in the deep lung, it can be 
expected the engineered particles to be less susceptible to phagocytosis due to their larger 
geometric size [63]. 
The different additives used affected the particles’ specific surface areas. As SEM imaging 
indicated (Figure 3.6), leucine facilitated formation of a sponge-like particles, within which the 
drug nanoparticles were embedded. Such structures inherently have an increased surface area 
with nanosuspension in the feedstock showing stronger effect than the suspension (Table 3.1). 
This was in agreement with the effective density measurements, which showed similar but 
opposite trend. Effective density of most formulations followed the trend of the bulk density 
except for S/Leu+AC. 
3.5.3 Dissolution rate  
Dissolution rate measurements were performed in order to characterize the developed 
formulations after deep lung deposition as determined by the NGI. The employed experimental 
setup was chosen to closely mimic the in vivo conditions after drug inhalation when particles are 
deposited on mucus or a surfactant layer of very limited volume (10-30 mL) that is not subject to 
mechanical agitation. In the employed setup, dissolution takes place in a very small fluid volume 
and the drug substance then diffuses through a membrane to a large compartment representing 
the sink of the bloodstream. 
No clear difference in the dissolution rate parameter kdiss between the NGI stages was found by 
data analysis using kinetic modelling that took into account the size of composite particles. Also, 
no difference of kdiss between the formulations was detectable. Significant non-zero values of the 
starting concentration C(0) were found in all cases. This is a compelling result of the analysis 
indicating that a considerable amount of drug powder that was deposited on the insert of the 
modified NGI cup dissolved already in the course of the sample preparation for the dissolution 
test. More interestingly, the deduced concentration values were in most cases above the solubility 
of the drug substance in the dissolution medium. The latter was determined in separate 
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experiments to be equal to 0.03 mg/mL. It was furthermore verified that the TPGS content of the 
samples, originating from WMM, produced concentrations in the dissolution media that did not 
exceed the critical micellar concentration of this excipient. This leads to the conclusion that the 
drug substance was probably present at least in part in an amorphous state in the deposited 
powder. This conclusion is supported by XRPD measurements showing that the API is partially 
amorphous after WMM as well as after spray drying (Appendix 8.1). It is also consistent with the 
observed fast onset of dissolution. C(0) values for the different NGI stages correlated positively 
with the drug amount deposited in the respective stages. C(0) values were further higher for those 
formulations that were produced by spray drying of nanosuspensions than for the formulation 
containing the non-milled drug and for the physical mixture, this being in agreement with the 
proposed reasoning for C(0) > 0. 
As a large proportion of the deposited drug was already dissolved at the beginning of the 
dissolution test, the deduced kdiss explained only a small part of the measured dissolution profile. 
This can be the reason for the observed variability of the kdiss results (Figure 3.11). It must be 
pointed out that the applied model-based data analysis made it possible to discern the 
contribution of the drug dissolved in the beginning and during the dissolution test. No differences 
in kdiss were found between the NGI stages for any of the formulations within experimental 
variability that would reflect variation in shape and/or surface roughness of particles. Also, no 
differences of kdiss between formulations were found despite the fact that the studied formulations 
differed considerably in their physical characteristics (Table 3.1). Additionally, similar kdiss values 
as for the engineered powders were found for the commercial product. 
To better understand this finding, dissolution experiments with the complete formulations of 
each formulation were carried out. The deduced values of dissolution rate parameter kdiss were 
not significantly different from each other in a statistical paired test with the exception of the two 
extreme values (Table 3.2). This is largely in agreement with the result of the dissolution test with 
the samples of the NGI stages. Only the physical mixture yielded a ten-fold smaller kdiss value. Thus, 
all spray dried formulations exhibited a dissolution rate that was consistent with the size 
distribution of the composite particles while their specific surface area, which differed greatly 
among formulations, did not seem to influence their dissolution rate. We suggest that this may be 
because composite particles of all formulations contained the same primary API nanoparticles. 
This would mean that dissolution rate is actually defined by the surface area of the API particles, 
which is the same in all formulations. From a dissolution point of view, no difference in the outer 
accessible surface area of the composite particles of the different formulations seems evident 
although their specific surface area differs (see also below). The same argument can be applied 
to the powders of the NGI stages that differ in particle size but exhibit no difference in dissolution 
rate, the latter being defined by the surface area of the primary API nanoparticles.  No difference 
in dissolution rate of formulation S/Leu+AC could be explained by the likely presence of very 
small drug particle sizes in the powder of the different stages caused by the homogeneity 
challenges described in Chapter 3.5.2. 
In the kinetic model that was developed for evaluating dissolution behaviour, dissolution of the 
solid drug substance in the inner compartment containing the inhalable formulation and 
permeation of the substance through the membrane are treated as consecutive processes 
entailing additionally a homogeneous substance concentration in the inner unstirred 
compartment. Model-based analysis allows delineation of the contribution of each kinetic step to 
the overall mass transport process. In the experiments with the individual NGI stages, values for 
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kdiss reflecting dissolution and P reflecting membrane permeation were independently estimated. 
P was relevant chiefly in connection with the permeation of drug that was already dissolved in 
the inner compartment in the beginning of the measurement. For the complete formulation 
powders, the dissolution parameter kdiss alone adequately explained the measured concentration 
data while the membrane permeability coefficient, P, was found not to be significant for 
describing the data. This was further substantiated by the performed analysis showing that the 
fit was not sensitive to the value of P at large P values while at small P values no good 
approximation was attained. Dissolved drug substance amount in the beginning of the 
measurement was negligible compared to the much larger amount contained in the used 
complete formulation powder. Hence, in the experiment of the complete formulation powders, 
dissolution appears to be the kinetically controlling process. 
Notably, kdiss values obtained on the one hand with powders from the NGI stages and on the other 
hand with the complete formulations were comparable, thus supporting the validity of the used 
model analysis. To further challenge the model, the plausibility of the kdiss values deduced from 
the fit of the model to the experimental data was examined. This parameter comprises the 





where all symbols were defined above. 
It should be first pointed out that a constant thickness of the diffusion boundary layer, which was 
independent of particle size, was used in the present model. The effect of diffusion boundary layer 
on particle dissolution kinetics in stirred and unstirred media has been the subject of research in 
recent decades [180–182]. Dissolution has been treated as a chiefly diffusion-controlled process 
whereas in case of convective diffusion the effective thickness of the diffusion boundary layer 
required to adequately describe dissolution kinetics was shown to depend on the size of the 
dissolving particles. For particle size in the range of a few micrometres up to tens of micrometres 
this thickness was demonstrated on theoretical grounds, and confirmed experimentally, to be 
comparable to the respective radius of the particles [68,183,184]. In the stirred USP II dissolution 
apparatus, a difference between the tangential fluid velocity and particle velocity was 
documented under non-slip conditions that increased at higher stirring rates, substantiating 
convective diffusion as dissolution controlling mechanism [185]. However, in the experimental 
arrangement employed in the present study, the dissolving particles are separated from the 
stirred outer bulk solution by a polymeric membrane and were therefore not subject to agitation. 
For this reason, the thickness of the diffusion boundary layer was not assumed to depend on 
particle size and a constant thickness was used in the dissolution model instead. 
For the diffusion coefficient, D, a typical value for a low molecular weight drug substance of 
approximately 5106 cm2/s [182–184], and for particle density, ρ, a representative value of the 
effective density measurement of 0.45 g/cm3, may be used. The shape factor, , denotes the 
deviation of the specific surface area of the particles from that of smooth spheres. The 
manufactured particles had an uneven surface (Figure 3.6) and a large specific surface area that 
depended on the formulation (Table 3.1). The effect of surface morphology on processes taking 
place at the solid surface such as dissolution and chemical reaction has been previously described 
by the use of fractal geometry [186,187] and time-dependent rate coefficients [188]. It has been 
recognized, however, that frequently the surface fractal dimension reflects an active surface of 
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the particle participating in the process that does not coincide with the total surface area of the 
particle but rather corresponds to an outer exposed region of the surface. Also, a distinction 
between the total (as determined by BET analysis) and the external surface area has been made, 
the latter being actively involved in the dissolution process [68]. For this reason, the simplifying 
assumption of assigning  the smallest possible value of  = 1 was made for the following 
discussion.  This is further consistent with the observation that there is no difference in kdiss 
between formulations despite their different specific surface areas.  
Using the above values for these quantities and a typical value of kdiss  = 2×10−5 cm4/(mg·min) 
deduced from the fitting, a thickness of the diffusion boundary layer of h=0.2 cm is estimated from 
eq. 3.14. This thickness, which is apparently consistent with the deduced dissolution kinetics, is 
far larger than values commonly reported for dissolution process controlled by convective 
diffusion. This discrepancy is attributed to the confined and unstirred inner compartment 
delimited by the polymeric membrane, in which dissolution takes place. Dissolution of solid 
particles in a stagnant unbounded (infinite) or bounded (confined) fluid has been treated 
theoretically and the effect of bulk concentration arising from confinement due to impermeable 
boundaries has been demonstrated [182,189]. The present situation, however, of dissolution in a 
confined and stagnant medium with permeable boundaries at which flux boundary conditions 
apply has, to the best of the authors’ knowledge, not been resolved. It is hypothesized that the 
unrealistically large thickness of the diffusion boundary layer found in this study is a result of the 
heterogeneity of the dissolved drug concentration due to the lack of convection in the 
compartment that contains the dissolving particles. Nevertheless, it should be pointed out that 
model-based analysis has been instrumental for unravelling the contribution of the processes 
that play a role in the dissolution experiment with the present experimental setup. 
3.6 Conclusion 
In this work, we have demonstrated the feasibility of preparation of low-density particles with 
superior aerodynamic properties and fast dissolution by wet media milling and subsequent 
application of particle engineering via spray drying. Interestingly, omission of the milling step 
greatly decreased fine particle fraction of the formulation. The FPF of a commercial product of 
the same API yielded very similar results as when WMM was not used. Therefore, equal 
importance should be given to drug pre-processing by particle size reduction and to spray drying 
when formulating engineered powders for inhalation to achieve advantageous performance over 
carrier-based formulations. The geometric size of the spray-dried particles was larger than that 
of micronized drug, additionally offering the advantage of evading phagocytosis. The choice of 
additives can largely influence the physical properties of the spray dried powders. Leucine 
facilitated formation of low-density powders irrespective of the use of WMM. However, it is 
important to note that the ability of an excipient to facilitate formation of low-density particles 
depends, in addition to the saturation solubility of the excipient, on the applied spray drying 
conditions under which the use of albumin as excipient may present a valid alternative. 
Very fast drug dissolution of deposited powders with no clear difference among individual NGI 
stages of each formulation or among the formulations was found by the model-based data 
analysis despite the large differences in particle shape and morphology among the formulations. 
We conclude that the primary drug particle properties govern dissolution rate and that 
processing can accelerate dissolution for example by amorphization. 
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The proposed combination of processes has the potential to become a platform technology for 
processing of poorly water-soluble drugs for inhalation. Advantageously, it is solely water-based 
and readily scalable. It was shown to be suitable for high drug load formulations and may also be 









4 Investigation of drug dissolution and uptake 
from low-density DPI formulations in an 
impactor integrated cell culture model
Besides deposition, pulmonary bioavailability is determined by dissolution of particles in the 
scarce epithelial fluid and by cellular API uptake. In the present work, we have developed an 
experimental in vitro model, which is combining the state-of-the-art next generation impactor 
(NGI), used for aerodynamic performance assessment of inhalation products, with a culture of 
human alveolar A549 epithelial cells to study the fate of inhaled drugs following lung deposition. 
The goal was to investigate five previously developed nano-milled and spray-dried budesonide 
formulations and to examine the suitability of the in vitro test model. The NGI dissolution cups of 
stages 3, 4, and 5 were transformed to accommodate cell culture inserts while assuring minimal 
interference with the air flow. A549 cells were cultivated at the air-liquid interface on Corning® 
Matrigel® -coated inserts. After deposition of aerodynamically classified powders on the cell 
cultures, budesonide amount was determined on the cell surface, in the interior of the cell 
monolayer, and in the basal solution for four to eight hours. Significant differences in the total 
deposited drug amount and the amount remaining on the cell surface at the end of the experiment 
were found between different formulations and NGI stages. Roughly 50% of budesonide was 
taken up by the cells and converted to a large extent to its metabolic conjugate with oleic acid for 
all formulations and stages. Prolonged time required for complete drug dissolution and cell 
uptake in case of large deposited powder amounts suggested initial drug saturation of the 
surfactant layer of the cell surface. Discrimination between formulations with respect to time 
scale of dissolution and cell uptake was possible with the present test model providing useful 
insights into the biopharmaceutical performance of developed formulations that may be relevant 
for predicting local bioavailability. The absolute quantitative result of cell uptake and permeation 
into the systemic compartment is unreliable, though, because of partly compromised cell 
membrane integrity due to particle impaction and professed leakiness of A549 monolayer tight 
junctions, respectively. 
4.1 Introduction 
Bioavailability of a drug is given, among others, by its interaction with the absorption epithelium 
under in vivo conditions [139]. This is commonly studied using in vitro cell culture systems. Cell 
cultures are mostly used under submerged conditions, which is a suitable approach for most drug 
delivery routes. However, pulmonary drug delivery presents a challenge as the submerged 
conditions do not properly reflect the in vivo system where air-liquid interface (ALI) exists. 
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Mimicking the in vivo situation in terms of liquid amount and composition in the cell culture 
system is therefore crucial when studying the interaction of deposited particles or droplets with 
the lung epithelium [46,157]. 
For evaluation of inhalation drugs’ performance in vitro, several established deposition systems 
exist, e.g. multistage liquid impinger, Andersen cascade impactor, or next generation impactor. 
They are indispensable in formulation development as they characterize the aerodynamic 
properties of a formulation by its classification according to aerodynamic particle size. In 
addition, it is highly desirable for complete and relevant characterization of the performance of a 
pulmonary formulation to study the behaviour of the inhalable fraction of particles with cells that 
simulate the in vivo state with respect to ALI. 
Studies that combine aerodynamically classified deposition and cell interaction are still rather 
rare. In some reports, pharmacopoeial instruments such as the twin-stage impinger [159,160], 
multistage liquid impinger [161,190], and Andersen cascade impactor [163,191] were 
transformed to accommodate a cell culture system. In one instance, also the NGI was used but 
without clear description of the NGI transformation [165]. It is important to note that deposition 
in all these systems is based on impaction, which induces certain cell stress [53]. More gentle 
deposition, however without aerodynamic classification, can be ensured using 
sedimentation-based systems, e.g., the Pharmaceutical Aerosol Deposition Device on Cell Culture 
(PADDOCC) [166], Air-Liquid Interface Cell Exposure (ALICE) System [167], or LTC-C Computer-
Controlled Long-Term Cultivation (CULTEX®) system [168]. Alternatively, insufflators such as 
MicroSprayer® Aerosolizer IA-1C can also be utilized [22,169]. 
In these experiments of deposition combined with cell interaction, immortalized, bronchial Calu-
3 cell line has been most commonly used. This cell line is generally appropriate for permeation 
studies that concern drug delivery to the bronchial region and produces a mucus layer when 
grown at ALI. Grown in submerged conditions, this cell line forms tight junctions with high 
transepithelial electrical resistance (TEER) values (≈ 1000 Ωcm2), which are quite lower 
(≈ 300 Ωcm2) when grown at ALI [192]. Notably, the ALI TEER values are comparable to values 
reported for the rabbit airway epithelium [192]. 
In the present work, we transformed the NGI to include the immortalized, alveolar A549 cell line 
for studying particle dissolution and drug uptake of aerodynamically classified powders from dry 
powder inhalers (DPI). The A549 cell line was used due to the focus on deep lung delivery. It 
currently represents a broadly used cell culture model for the alveolar epithelium [193] and has 
not been used in combination with aerodynamic powder classification before. These cells possess 
phenotype of epithelial type II cells – one of the two major cell type present in the alveolar region 
[53]. A549 cells have been extensively characterized both under submerged and ALI conditions 
and it was shown that TEER, even though generally low (≈ 150 Ωcm2), does not depend on the 
conditions used. Also, the cells were shown to produce surfactant when grown on ALI. 
Additionally, positive staining of these cells for zonula occludens-3, occluding, and claudin-2 
suggests the formation of tight junctions in the epithelial barrier [22,194]. It is acknowledged that 
A549 culture exhibits lower TEER compared to submerged primary alveolar type II cells (e.g. 
hAEpC [195,196]); however, no in vivo TEER values are available as a reference. Still this cell line 
may not be suitable for permeation studies of drugs across the epithelium to predict systemic 
bioavailability as indicated before [53,197]. 
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In this work, the next generation impactor, which is the state-of-the-art pharmacopoeial method 
for aerodynamic testing of inhalation formulations in the industry, was employed and its cups 
were adapted to incorporate low-profile Millicell® cell culture insert for deposition of 
aerodynamically classified powders on the surface of A549 cells. The purpose of this work was to 
develop an in vitro experimental model for investigating factors that are relevant for local 
bioavailability of pulmonary formulations under conditions closely reflecting the in vivo situation. 
With this model, the effect of formulation properties and the potential role of the impactor stage 
should be elucidated. 
Our aim was to a) evaluate dissolution upon deposition and cellular drug uptake of previously 
developed low-density powders for inhalation with improved lung deposition [198], and b) 
examine suitability of this experimental arrangement that combines NGI with the A549 cells to 
evaluate bioavailability and performance of pulmonary formulations intended for local delivery 
such as to treat bacterial infection, inflammation, or lung cancer. Drug products for these 
indications represent the majority of inhalation products on the market [199]. 
4.2 Materials and methods 
4.2.1 Materials 
Matrigel® matrix (growth factor reduced; Corning®, Germany) was used at a concentration of 
≈ 4 g/L. In vitro toxicology assay kit and Millicell® cell culture inserts PICM0RG50 (30 mm 
diameter, 0.4 µm pore size, 4.2 cm² surface area; Millipore by Merck, Germany) with PTFE 
membrane were purchased from Sigma-Aldrich (Switzerland). LIVE/DEAD™ cell imaging kit was 
obtained from ThermoFisher Scientific (USA). Ammonium formate and formic acid were from 
Fluka (Switzerland). Ethanol (EtOH) and acetonitrile (both HPLC grade) were purchased from 
J.T.Baker (The Netherlands). Ultrapure water (Milli-Q®, Millipore, Switzerland) was used for all 
experiments. 
4.2.1.1 A549 cell culture 
Experiments were done with the human alveolar epithelial type II cell line A549, which was 
kindly donated by B. Rothen-Rutishauser (Adolphe Merkle Institute, University of Fribourg, 
Switzerland). The cells were cultured in RPMI 1640 (Gibco, Life Technologies Europe B.V., 
Switzerland) supplemented with 10% (v/v) fetal bovine serum (FBS; PAA Laboratories, Chemie 
Brunschwig AG, Switzerland), 1% (v/v) L-Glutamine (Life Technologies Europe, Switzerland) and 
1% (v/v) penicillin/streptomycin (Gibco, Switzerland). The cells were kept in a humidified 
incubator at 37°C and 5% CO2. Cell concentration was calculated using Trypan blue exclusion 
method. For the powder deposition experiments, cells of passage numbers 6 - 10 were seeded in 
low height cell culture inserts (PICM0RG50) at a density of 1.19 × 105 cells/cm2. These inserts 
were selected having low sidewalls in order for them to fit in the transformed dissolution cup. 
4.2.2 Methods 
4.2.2.1 Matrigel® bioprinting 
Due to the hydrophobic nature of the PTFE membrane, it was necessary to treat the inserts with 
a protein matrix such as Matrigel® before application of the cells on the membrane. The bioprinter 
BioFactory™ (regenHU Ltd., Switzerland) equipped with a contact dispensing microvalve CF300 
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(MVC03-006; regenHU Ltd.; nozzle diameter 0.3 mm) was used to print Matrigel® matrix on the 
Millicell® cell culture inserts using modified method of Horváth et al. [200]. Bioprinter parts that 
were in contact with Matrigel® were cooled in advance down to 5°C to prevent Matrigel® gelling 
during bioprinting. The applied bioprinting parameters were dispensing pressure of 0.27 kPa, 
dosing distance of 0.2 mm, and valve opening time of 110 µs. 
4.2.2.2 Cell growth on Matrigel®-coated inserts 
One mL of A549 cell suspension was evenly distributed on wetted, Matrigel®-coated insert 
membrane and the inserts were placed into a 6-well plate where each well contained 1 mL of 
supplemented RPMI medium. The cells were grown in the incubator until confluency for 3 days 
while exchanging the medium in both apical and basal chamber on day 2. On day 3, the apical 
medium was removed and the cells were kept exposed to air, creating an air-liquid interface 
(ALI). The cells were at ALI for 12 - 18 hours prior to further use, which ensured surfactant layer 
formation. The presence of surfactant layer on the cells was verified by the droplet method as 
reported before [22]. 
4.2.2.3 Powder deposition on cell cultures 
In order to deposit powder on the cell surface, the NGI dissolution cups (Copley Scientific, UK) 
had to be first transformed to allow accommodation of a cell culture insert. Figure 4.1 illustrates 
the changes made to the NGI dissolution cup. The aerodynamic particle size distribution of a 
powder before and after these changes was assessed. 
 
Figure 4.1 Schematics of NGI dissolution cup transformed to allow placement of a cell culture 
insert. 
For the deposition experiment, insert with cells at ALI was placed into the transformed NGI cup 
in either stage 3, 4, or 5, which at 68 L/min have aerodynamic cut off diameters of 4.16 - 2.64 µm, 
2.64 - 1.56 µm, and 1.56 - 0.88 µm, respectively. The transformed NGI was operated as described 
earlier [198] using the RS01 Mod. 8 (Plastiape S.p.a., Italy) dry powder inhaler; only the powder 
fill weight in the capsules was decreased to ≈ 0.2 mg in order to reduce number of particles 
depositing on the cell surface. The small powder amounts were weighted using an analytical 
balance (type XP2U Mettler Toledo, Switzerland) with precision of 0.1 µg. After the exposure, the 
insert was placed into a 6-well plate filled with 1 mL of RPMI 1640 medium supplemented with 
1% (v/v) L-Glutamine and 1% (v/v) penicillin/streptomycin and kept in an incubator. Samples 
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of 100 µL were taken from the basal medium for up to eight hours and this volume was 
immediately replenished with fresh medium. At the end of the experiment, samples’ cell surface 
was washed with 1 mL of cold EtOH:H2O (50:50) mixture to collect and quantify any remaining 
budesonide on the apical side. After this step, the cells were lysed with 1% Triton™ X-100 (Sigma 
Aldrich, Switzerland) in water (0.75 mL) for 30 minutes at 37°C while gently stirring on an orbital 
shaker. 
The stage drug amount was calculated as the sum of the drug amounts found in all three 
compartments, i.e., the wash from cell surface, in the cell interior, and the basal medium at the 
end of the experiment. The total drug amount was calculated as the sum of the stage drug amounts 
from stage 3 - 5. The terms defined here will be used hereinafter.  
Table 4.1 summarizes the formulations with nominal drug load of 43% used for the cell exposure 
experiments. Preparation of the formulations is in detail described in [198]. 




















5.04 ± 0.02 
22 
NS/Leu Nanosuspension Leucine 5.30 ± 0.03 46 
NS/Alb Nanosuspension Albumin 5.01 ± 0.10 39 
NS/ Nanosuspension - 5.30 ± 0.06 18 
 
4.2.2.4 HPLC-UV-MS 
Budesonide (B) and budesonide oleate (BO) were analysed by HPLC-UV-MS series 1200 equipped 
with a degasser G1379B, a binary pump G1312A, an autosampler G1367B, a thermostat G1330B, 
a column oven G1316A, a variable wavelength detector G1314B, and a single quadrupole MS 
detector G6130A (all Agilent Technologies, USA). A C-8 reversed phase column (Kromasil® 100, 
5 µm, 100 × 2.1 mm; Dr. Maisch, Germany) and mobile phase consisting of (A) ammonium formate 
buffer (25 mM, pH 3.2) : ACN (50:50) and (B) ammonium formate buffer (125 mM, pH 3.2) : ACN 
(10:90) were used. To analyse the calibrants of the first experiment, an isocratic mode was used 
with A:B = 100:0 a flow rate of 0.2 mL/min and a run time of 10 min. The composition of the 
mobile phase was varied in a gradient mode for all samples and the calibrants of the second 
experiment with a flow rate of 0.2 mL/min and a runtime of 50 min: 0 - 5 min A:B = 100:0, 
5 - 15 min linear change to A:B = 0:100, 15 - 40 min A:B = 0:100, 40 - 41 min linear change to A:B 
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= 100:0, and 41 - 50 min A:B = 100:0. The samples were cooled in the autosampler to 4°C and the 
column temperature was set to 25°C. The ions were generated by atmospheric pressure 
electrospray ionization and the MS detector was run in SIM mode at positive polarity with 
capillary voltage 4000 V, fragmentor 100 V, drying gas flow 10 L/min, drying gas temperature 
350°C, and nebulizer pressure 30 psig. Budesonide and budesonide oleate were detected at 
240 nm in UV. Budesonide was detected at m/z 413.2 and 431.2 and budesonide oleate at m/z 
677.5 and m/z 685.5 in MS corresponding to their protonated fragments and parent compounds, 
respectively. The metabolite was quantified with the calibration curve of budesonide in UV. The 
LOQ of budesonide for an injection volume of 50 µL was 0.07 µM in UV. 
4.2.2.5 Cell integrity measurement 
The cell damage induced during the experiment was assessed using a TOX7 cytotoxicity kit based 
on lactate dehydrogenase (LDH) quantification in the basal medium (Sigma Aldrich, Switzerland). 
An insert submerged in 5 mL of serum-free RPMI 1640 containing 10% Triton™ X-100® was used 
as a positive control. As a negative control, insert placed on the serum-free medium without any 
further treatment or exposure was used. Samples of the basal medium as well as positive control 
were diluted 10x with water prior to processing. LDH was quantified in triplicate 
spectrophotometrically in a 96-well plate at 490 nm. Background absorbance was measured at 
690 nm and subtracted from the primary absorbance measurement at 490 nm. Additionally, 
absorbance of the serum-free RPMI 1640 medium was subtracted from all averaged values. Cell 
damage was calculated using the following equation (eq. 4.1): 
𝐶𝑒𝑙𝑙 𝑑𝑎𝑚𝑎𝑔𝑒 (%) =
𝐴𝑏𝑠 − 𝐴𝑏𝑠  
𝐴𝑏𝑠  − 𝐴𝑏𝑠  
× 100 (4.1) 
4.2.2.6 LIVE/DEAD™ assay 
Right after deposition of the formulation NS/Leu+AmC on stage 3, 4, and 5, the cells were stained 
with the commercially available LIVE/DEAD™ Cell Imaging Kit (Invitrogen™ by Thermo Fisher 
Scientific, USA). According to the manufacturer, the Live Green was mixed with the Dead Red and 
1 mL was added on the apical side of the insert and incubated for 30 min at room temperature. 
The staining was removed, PBS was added to the basal side and the cells were imaged with a 
fluorescence microscope (Olympus IX83, Japan). As controls non-stained and stained living cells 
and stained dead cells (30 min treatment of living cells with 70% MeOH) were used. The controls 
did not undergo deposition in the NGI. 
4.2.2.7 Kinetic modelling 
The process of drug uptake into the cells after particle deposition, drug metabolism and release 
into the basal solution was modelled in order to estimate kinetic parameters that would allow a 
quantitative description of the process. The time-dependent change of drug amount on the cell 
surface (eq. 4.2), drug and metabolite amount in the cells, (eq. 4.3) and (eq. 4.4), respectively, and 




= −𝑘 𝐵  (4.2) 
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= 𝑘 𝐵 − 𝑘 𝐵 − 𝑘 (𝐵 − 𝐾 ∙ 𝐵 )  (4.3) 
𝑑𝐵𝑂
𝑑𝑡
= 𝑘 𝐵   (4.4) 
𝑑𝐵
𝑑𝑡
= 𝑘 (𝐵 − 𝐾 ∙ 𝐵 )  (4.2) 
where, BA is budesonide mass in the apical compartment i.e., on cell surface, BC is budesonide 
mass in the cell, BOC is budesonide oleate mass in the cell, BB is budesonide mass in the basal 
solution, ku is uptake rate constant of drug from the cell surface into the cell, km is metabolic rate 
constant of drug to its oleate metabolite, kr is release rate constant of the drug from the cell into 
the basal solution, K is partition coefficient of drug between the cell interior and the basal 
solution, and t is time. All mass transfer and conversion steps were treated as first order 
processes and equilibrium of dissolved drug mass was assumed to ensue between the cell interior 
and the basal compartment. 
The above equations were solved using numerical differentiation and the system was at the same 
time fitted by least square approximation simultaneously to all experimental data for BA, BC, BOC, 
and BB whereby optimal values of the parameters ku, km, kr and K were estimated. The software 
EASY-FIT® [178] was employed. Boundary conditions at t=0 of BA=BA(0) and BC=BOC=BB=0 were 
applied, whereas BA(0) was set equal to the sum of recovered drug amounts in all compartments 
including the metabolite at the end of the experiment. 
4.2.2.8 Statistical analysis 
Statistical analysis of the data was done using Excel’s two-way ANOVA (Microsoft, USA). Stage 
drug amount was analysed as absolute amount, while budesonide and budesonide oleate in the 
compartments were analysed as relative amounts. 
4.3 Results and discussion 
4.3.1 Powder deposition and its pattern in transformed NGI 
Powder was deposited on an insert placed either in stage 3, 4, or 5, which are the stages 
contributing to the largest extent to so-called fine particle fraction (FPF). The FPF is the 
percentage of the powder with an aerodynamic diameter below 5 µm and it provides an estimate 
of the drug dose effectively delivered to the lungs. The used formulations were found to differ 
markedly in their FPFs using the original, non-transformed NGI (Table 4.1); their properties that 
are responsible for this behaviour are extensively discussed elsewhere [198]. 
In the present work utilizing transformed NGI, the stage drug amount was determined as the sum 
of the quantities of budesonide and its metabolic product measured in the three investigated cell 
compartments, i.e., the apical compartment constituting the cell surface, the cellular 
compartment, and the basal solution, at the end of the experiment. Deposited drug amount 
differed significantly between formulations and between stages of the NGI, the effect of both the 
formulation and the stage being very significant (p<0.01) as determined by two-way ANOVA 
(Figure 4.2, Table 4.2). 
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df Mean square 
(MS) 
F-ratio p-value Critical F-value 
NGI stage 156.97 2 78.49 40.12 0.0000 3.68 
Formulation 88.85 4 22.21 11.35 0.0002 3.06 
Interaction 32.03 8 4.00 2.05 0.1103 2.64 
Error 29.34 15 1.96    
Total 307.20 29     
 
Total drug amount decreased among formulations in the order: 
NS/Leu+AmC > NS/Leu > NS/Alb > NS/ > S/Leu+AmC 
The amount deposited in individual stages decreased for all formulations in the order stage 3 > 
stage 4 > stage 5, this trend being stronger for the formulations NS/Alb, NS/, and S/Leu+AmC 
(Figure 4.2). These results are fully consistent with powder deposition measured with the NGI 
prior to its transformation for accommodating the inserts with the cell culture [198], 
demonstrating that this transformation did not influence the deposition/classification 
performance of the NGI.  Ranking of the total drug amount in the three stages for the studied 
formulations was virtually the same before and after NGI transformation (columns, Figure 4.2), 
which additionally confirmed the negligible influence of this transformation on deposition.  It 
should be noted that this comparison can only be performed in terms of ranking as the amount of 
powder in the capsules and the surface area of deposition varied between the two situations. 
 
Figure 4.2 Budesonide deposition in transformed NGI in stages 3, 4, and 5 given as raw data (dots) 
and mean total drug amount of the three stages of all formulations (left set of columns) depicted on left y-
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axis. Total drug amount of the three stages of all formulations in non-transformed NGI (right set of 
columns) depicted on right y-axis. 
This verification was essential for making sure that the aerodynamics and hence powder 
deposition pattern were not markedly affected by the transformation of the NGI. In fact, the 
surface of the cell monolayer lay somewhat lower than the surface of the impaction cup of the 
non-transformed NGI in order to prevent the upper edge of the insert sidewall from protruding 
above the cup’s surface (Figure 4.1). 
4.3.2 Budesonide compartment distribution 
Budesonide was detected in significant amounts in all compartments of the cell culture for all 
formulations (Figure 4.2, Figure 4.3). The percent drug amount recovered from the cell surface at 
the end of the experiment depended very significantly (p<0.01) on the formulation (Table 4.3), 
NS/Leu+AmC and NS/Leu exhibiting larger recovery amounts compared to the other 
formulations (Figure 4.3). This amount was larger for stage 3 compared to stages 4 and 5 (Figure 
4.3), the effect of stage being also statistically very significant (p<0.01) by the two-way ANOVA 
(Table 4.3). 
 
Figure 4.3 Mean percent drug distribution in the compartments of the in vitro test system (B = 
budesonide, BO = budesonide oleate) for the different formulations and NGI stages 3, 4 and 5 (n=2). 
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Table 4.3 ANOVA Budesonide amount in apical compartment (%) (significant factors are 





df Mean square 
(MS) 
F-ratio p-value Critical F-value 
NGI stage 151.22 2 75.61 8.61 0.0032 3.68 
Formulation 246.55 4 61.64 7.02 0.0022 3.06 
Interaction 20.04 8 2.50 0.29 0.9607 2.64 
Error 131.79 15 8.79    
Total 549.60 29     
 
On the contrary, the percent amount of budesonide determined at the end of the experiment in 
the interior of the cells and in the basal solution did not depend on the formulation or the stage 
under consideration ( 
Table 4.4 and Table 4.5). 
 






df Mean square 
(MS) 
F-ratio p-value Critical F-value 
NGI stage 39.76 2 19.88 0.66 0.5305 3.68 
Formulation 107.89 4 26.97 0.90 0.4898 3.06 
Interaction 48.13 8 6.02 0.20 0.9863 2.64 
Error 450.80 15 30.05    
Total 646.59 29         
 






df Mean square 
(MS) 
F-ratio p-value Critical F-value 
NGI stage 62.55 2 31.28 1.07 0.3690 3.68 
Formulation 82.40 4 20.60 0.70 0.6024 3.06 
Interaction 15.20 8 1.90 0.06 0.9997 2.64 
Error 439.97 15 29.33    
Total 600.12 29         
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The release of drug into the basal solution exhibited a similar pattern as a function of time for all 
formulations and impactor stages, seemingly reaching an equilibrium within approximately two 
hours (Figure 4.4). In addition, large amounts of budesonide oleate, a drug metabolite reported 
previously to be formed in lung cells [201,202] were detected in the cell interior (Figure 4.3). The 
relative metabolite amount depended on the stage (p<0.05) (Table 4.6) with stage 3 exhibiting 
generally smaller amounts than the other two stages. The total cell content (B+BO) (in %) 
depended on the formulation (p<0.01) (Table 4.7Table 7), NS/Leu+AmC and NS/Leu exhibited a 
smaller amount than the other formulations. The ANOVA in Table 4.3 to Table 4.7 were carried 
out with the relative drug amount for the different compartments expressed in percent of the 
total amount deposited in the respective impactor stage. 
 
Figure 4.4 Budesonide concentration in the basal compartment as a function of time for the 
different formulations and NGI stages 3, 4 and 5. Dot symbols give individual raw data and lines connect 
average points.   
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Table 4.6 ANOVA Budesonide oleate amount in cell compartment (%) (significant factors are 





df Mean square 
(MS) 
F-ratio p-value Critical F-value 
NGI stage 229.11 2 114.56 5.56 0.0156 3.68 
Formulation 167.25 4 41.81 2.03 0.1418 3.06 
Interaction 33.13 8 4.14 0.20 0.9862 2.64 
Error 309.14 15 20.61    
Total 738.63 29         
 






df Mean square 
(MS) 
F-ratio p-value Critical F-value 
NGI stage 101.30 2 50.65 2.28 0.1364 3.68 
Formulation 469.46 4 117.36 5.29 0.0074 3.06 
Interaction 30.51 8 3.81 0.17 0.9916 2.64 
Error 333.01 15 22.20    
Total 934.28 29         
 
4.3.3 Drug dissolution and cell uptake 
It can be inferred from the above analysis that upon powder deposition, no complete dissolution 
of drug particles took place in the course of the experiment for formulations NS/Leu+AmC and 
NS/Leu, particularly on stage 3, which could be attributed to the comparatively large amount of 
deposited powder in the noted instances. The observed disproportionate distribution of drug in 
the investigated compartments between formulations and stages is illustrated in Figure 4.5 
showing that the percentage recovered from the cell surface increased with increasing deposition 
while the percentage released in the basal solution did not, and is considered to be due to 
saturation of the surfactant-rich fluid lining of the alveolar cells with drug. This layer consists 
primarily of phospholipids including saturated and unsaturated phosphatidylcholine, and water 
[203] and has been described to have a thickness on average of 0.1 µm [204]. The solubility of 
budesonide in the model lung surfactant preparation SurvantaTM was reported to be 32 mg/mL 
[205]. For the used inserts with a surface area of 4.2 cm2, a volume of the surfactant cell lining of 
0.042 µL and a maximal dissolvable drug amount in this volume of 3.12 nmol (1.34 µg) can be 
estimated based on these data. The drug amount deposited on the cells was for all formulations 
and nearly all stages well above this margin (Figure 4.2). The drug amount recovered from the 
cell surface at the end of the experiment was for formulations NS/Leu+AmC, NS/Leu, and NS/Alb 
in stage 3 roughly equal to or somewhat below this margin (Figure 4.2 and Figure 4.3) supporting 
the proposed interpretation of saturation of the surfactant layer and hence no complete 
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dissolution of deposited drug until the very end. In all other cases, considerably smaller drug 
amounts were recovered from the apical compartment. The larger relative drug amount 
remaining on the cell surface correlated with the smaller relative amount of metabolite found in 
the interior of the cells in the same inserts. No other effect of formulation or difference between 
stages with respect to drug dissolution or cell uptake was detected. Also, no interaction between 
the stage and formulation in respect to any of the dependent variables was found to be significant 
in the two-way ANOVA (Table 4.2 to Table 4.7). 
 
Figure 4.5 Dependence of relative drug amount at the end of the experiment in the apical 
compartment (left panel) and in the basal solution (right panel) on the total deposited absolute drug 
amount. Black symbols, dark grey symbols and light grey symbols depict results of stage 3, stage 4 and 
stage 5, respectively, each for the five formulations. Dot symbols give individual raw data. 
These results therefore imply that while for small deposition amounts dissolution was rather 
quick and equilibrium of drug distribution among the investigated compartments was reached, 
dissolution of comparatively large deposited drug amounts took place almost throughout the 
duration of the experiment, i.e. four to eight hours. Hence, dissolved drug appeared to be 
distributed in the same fashion for all formulations and stages among the compartments as 
indicated by the very similar release profiles into the basal solution (Figure 4.4), while 
undissolved drug, if any, remained on the cell surface (Figure 4.5). Incidentally, no particle uptake 
by phagocytosis by the epithelial cells was assumed to take place [22]. Kinetic analysis of the 
results supports this view. An empirical first order rate constant ku was used in the kinetic model 
to describe the appearance of drug in the interior of the cell (Figure 4.6). This is a combined rate 
constant capturing the consecutive steps of dissolution and cell entry of the drug since it was not 
feasible in the performed experiments to delineate these two steps. This rate constant acquired 
its smallest values for formulations NS/Leu+AmC and NS/Leu, particularly in stage 3, and was 
higher for the other formulations in this stage and in stages 4 and 5. This is consistent with the 
proposed interpretation of the data based on the two-way ANOVA, suggesting a protracted 
dissolution and uptake of the drug by the cells for the larger amounts of deposited powder. No 
systematic variation of the other two fitted parameters (kr, K) was found (not shown). 
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Figure 4.6 Uptake rate constant for NGI stages and formulations. 
The rate of particle dissolution on the lung epithelium is relevant not only in the context of the 
onset of pharmacological action but the time a particle takes to dissolve is of essence because 
particles may be cleared by scavenger macrophages [206], which are present on the alveolar 
surface, potentially resulting in diminished bioavailability. Phagocytic activity depends on 
particle size with a maximum around 1 µm [63] and has a half-life of roughly two to three hours 
[58]. The time required for complete dissolution estimated from this study and the half-life 
calculated from the constant ku for high drug deposition amounts are comparable to the 
phagocytosis half-life, indicating that indeed phagocytosis can impair bioavailability. These 
considerations point out the relevance of the present measurements for predicting performance 
of pulmonary delivery.  
Earlier work using the NGI dissolution cups and a modified USP2 dissolution apparatus [198] 
demonstrated almost instantaneous dissolution of deposited budesonide and no differences of 
dissolution rate between formulations or stages. The different result of the present study is most 
likely because of the above-mentioned  very limited fluid volume that is available for dissolution 
on the cell surface. Although the drug amount in the present study was one fifth of that in the 
earlier work, the fluid volume on the alveolar surface is still a lot smaller than the one used in the 
modified USP2 apparatus with the NGI dissolution cups. 
Budesonide entering the cells was efficiently metabolized to budesonide oleate. The metabolite 
amount was at the end of the experiment roughly twice as much as the amount of budesonide in 
the cells. The two species found in the cell interior generally accounted together for more than 
half of the deposited drug amount. The accumulation of drug in the cells is probably related to the 
relatively high lipophilicity of budesonide (log(octanol/water partition coefficient) = 2.67) [207] 
and the estimated two to four orders of magnitude higher lipophilicity of its metabolite [201]. 
Budesonide oleate was not detected in any other compartment. The total amount in the cell 
interior was followed by the drug amount in the basal solution and the amount on the cell surface. 
Hence, in the duration of the experiment, the vast majority of deposited drug can be considered 
to become bioavailable in the pulmonary tissue.  
However, the drug amount detected in the basal solution cannot be used as a measure of 
absorption or systemic bioavailability because the used A549 cell line forms tight junctions that 
are much leakier than those of primary alveolar cells [30,53] and presumably of the in vivo 
alveolar epithelium. On the other hand, the transport of budesonide through the cell monolayer 
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likely follows a transcellular pathway as evidenced by the large accumulation of drug in the cells 
and therefore would not be expected to be influenced by the leakiness of tight junctions. Still, the 
A549 cell model is for the above reason not universally appropriate for predicting systemic 
pulmonary bioavailability, much less so for rather hydrophilic drug molecules. Nevertheless, cell 
uptake of the drug may be considered to be relevant when local bioavailability is of the essence 
as in the present situation, since the site of budesonide drug action is located in the epithelial cells 
[208]. The extent of cellular accumulation will likely decrease when the basal compartment 
represents a sink such as in the in vivo situation. Yet, the presented experiments provide valuable 
insights into the process and kinetics of drug dissolution and cell uptake following powder 
deposition onto the cell surface. The obtained result is instructive of the efficiency of local delivery 
by pulmonary administration.  
Transfer of the present results to the in vivo situation in the context of an in vitro – in vivo 
correlation, IVIVC, would comprise the estimation of local drug concentration in the lung. This 
would be valuable as the difficulty of measuring drug levels in the epithelial lining and tissue has 
been acknowledged as major obstacle in pulmonary IVIVC [139]. In this respect, the site of local 
pharmacologic action and hence the target site of drug delivery play an important role. 
Conductive airways have a comparatively small surface area and are covered by a small volume 
of aqueous mucus while the alveolar area is covered by a comparatively larger volume of 
surfactant-rich fluid. The volume and nature of the fluid that is available for drug dissolution 
should be referred to the dose reaching the lung region of interest for an IVIVC on the background 
of the results of the present study. While IVIVC is beyond the scope of this article and volumes of 
the involved physiological fluids are still a matter of debate, this discussion indicates the 
predictive potential of the work.  
It should be finally pointed out that the present analysis revealed no differences between the 
studied formulations with respect to cellular processing such as uptake, metabolism and release 
into the basal medium other than what is elicited by the differences in the deposited amount. Also, 
a comparable behaviour among the studied NGI deposition stages was discovered. Given that for 
all formulations and different deposition stages the underlying drug substance nano-suspension 
was identical, this then leads to the conclusion that this is performance-determining. 
4.3.4 Cell integrity 
Cell integrity in the developed experimental setup was evaluated by lactate dehydrogenase assay 
(LDH) and LIVE/DEAD™ cell imaging assay using optical fluorescence microscopy. LDH results 
obtained at the end of the experiment (Table 4.8) indicate that the experimental procedure had 
an adverse effect on the cultured cell monolayer. This presumably occurred by the action of 
particle deposition on the cell surface causing some degree of damage to the cell membrane, 
which led to the leakage of the intracellular enzyme. No systematic effect of formulation or 
impactor stage on LDH was ascertained by two-way ANOVA (not shown). It should be pointed out 
that these measurements reflect the largest possible adverse effect as they were taken at the end 
of the experiment at a duration of four to eight hours. Blank experiments performed without the 
powder formulation interestingly showed that the air stream alone also affected the integrity of 
the cell membrane but to a much smaller extent. 
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Table 4.8 Cell damage induced in the course of the experiment according to stage and formulation a 
  S3 (%) S4 (%) S5 (%) 
NS/Leu+AmC 8.9 ± 6.3 13.4 ± 2.6 18.4 ± 5.4 
S/Leu+AmC 10.0 ± 3.4 13.9 ± 2.9 15.3 ± 4.0 
NS/Leu 19.1 ± 12.8 15.9 ± 10.9 14.9 ± 8.1 
NS/Alb 20.9 ± 6.1 24.3 ± 2.9 31.3 ± 5.8 
NS/- 20.5 ± 14.6 5.9 ± 3.5 15.5 ± 1.5 
Air stream 0.6 2.0 1.9 
a values represent average ± absolute standard error (n=3 except for air stream where n=1) 
Optical microscopy demonstrated a confluent cell monolayer that remained largely intact in the 
course of the experiment (Figure 4.7). This figure depicts typical results obtained with one of the 
formulations. The employed staining revealed that the vast majority of the cells remained 
attached and in a live state, while a relatively small number of cells appeared dead. For impactor 
stages 3 and 4, the dead cells seemed to be randomly distributed across the monolayer whereas, 
interestingly, for stage 5 dead cells were concentrated in specific spots. These spots corresponded 
exactly to the nozzles of this stage of the NGI, which are smaller and more frequently distributed 
over the cup than the nozzles of the other two stages. These images, therefore, provide indirect 
evidence that the impact of particles is responsible for damage of the cell monolayer. Overall, 
however, the extent of damage detected by the microscopic assay seemed rather modest. This 
assessment is corroborated by the fact that the cells maintained a strong metabolic activity 
throughout the experiment as evidenced by the formation of large quantity of the oleate 
metabolite of the drug. 
 
Figure 4.7 Images of cells stained using a LIVE/DEAD™ Cell Imaging kit (live and dead cells are 
shown in green and red, respectively). Images recorded after deposition of one formulation in different 
NGI stages versus control. In stage 5 the position of the nozzles above the cell monolayer is suggested. 
Scale bar represents 200 µm. 
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Taken together, the adverse effect on the cell monolayer caused by the experimental procedure 
appeared stronger when assessed by the LDH assay compared to microscopic imaging. It should 
be noted, however, that the LDH assay detects membrane injury which is not necessarily linked 
to cell death. Since cell membrane integrity is defining for molecular trafficking in and out of the 
cell, the cellular uptake of the drug determined in this work may be overestimated. On the other 
hand, the impact of partial loss of membrane integrity on cell uptake may arguably be less severe 
for lipophilic compounds, such as budesonide that readily partition into the lipid domain of the 
membrane than for hydrophilic drugs. In any case, utmost caution is required when transferring 
these results to the in vivo situation. The combination of NGI with A549 cell culture appears hence 
to be subject to similar drawback with respect to cell stress as suggested for other impingers in 
combination with cell lines [53]. Its usefulness therefore for assessing local pulmonary 
bioavailability in absolute terms may be compromised. Yet the model of the present study 
provided valuable insights into the comparative evaluation of stage-dependent formulation 
performance concerning particle dissolution and cell drug uptake and metabolism. 
4.4 Conclusion 
Transformation of the NGI to allow combination of aerodynamic formulation performance 
evaluation with powder ‒ alveolar cell interaction was successful. This provided insights into NGI 
stage-dependent particle deposition on cell surface, dissolution, and subsequent drug uptake and 
metabolism by the cells. Cell damage by the impaction, however, could not be entirely avoided. 
Drug processing by the cells did not depend on stage or formulation. Discrimination between 
formulations was possible due to the difference of deposited powder amount. Deduced time 
frame of drug dissolution in the surfactant layer surface was shown to be dependent on 
deposition amount and be rather long (≥4 hours) for larger amounts of deposited powder despite 
the nano-range size of API particles, and to be in fact longer than reported before, implying 
potential negative impact on bioavailability. Drug transport in the A549 cell monolayer appeared 
to take place transcellularly and strong drug metabolism was evident. Stage-specific distribution 
of drug in different cell compartments and drug amount in each compartment are relevant for 
drug delivery and therapeutic effect, respectively, and have not been described in an in vitro 
system before. The developed experimental model provides useful insights and ought to be 








5 Final conclusion and Outlook 
Modern dry powder pulmonary drug delivery has seen its advent in the 1940s with the first 
lactose-based powders, however rather little advancement, compared to for example oral 
delivery, has been done in this field in the decades since then. [1,209] Yet, the field remains an 
important one for local drug delivery, as it is widely used for treatment of chronic diseases such 
as asthma or COPD. It is also becoming an increasingly interesting alternative to intravenous 
administration due to the possibility to deliver drugs systemically via the alveolar region. 
Nonetheless, most of the marketed locally acting products still use decades-old technologies such 
as dry blending to create formulations of only moderate pharmaceutical performance. 
This work employed and combined industry-viable manufacturing processes to create inhalation 
powders of superior pharmaceutical performance and prolonged residence time due to 
favourable physical-chemical powder properties. For this, wet media milling was used to process 
a poorly water-soluble model drug substance (budesonide), which led to creation of drug 
nanosuspension. The nanoparticles were stabilised by TPGS, which was selected from an array of 
investigated stabilisers based on the possibility to achieve smallest median particle size and span. 
Subsequently the nanosuspension was spray dried together with additives selected for their 
potential to favour drying at high Péclet numbers. Particle engineering approach was applied 
through careful selection of process parameters and formulation composition. Powders 
containing particles of large geometric particle size and low density were successfully prepared. 
Several powders showed notably superior aerodynamic properties compared to the commercial 
product and fast dissolution was achieved for all powders. Thanks to the larger particle size, the 
powders would also have the potential of prolonged residence time due to lower probability of 
being removed by phagocytic clearance. An important finding of this work was that only by 
combining both manufacturing processes powders of all the above-mentioned properties could 
be achieved. When wet media milling was omitted, aerodynamic performance was similar to that 
of the commercial, carrier-based budesonide drug product. Dissolution of aerodynamically 
classified powders has been studied in detail using a modified USP2 system to better understand 
the advantages drug nanoparticles bring into the formulation and to study the different 
dissolution kinetics based on secondary (i.e. microparticle) size. However, despite the notable 
differences in particle shape and morphology among the formulations, very fast drug dissolution 
of deposited powders was observed. No clear difference among individual impactor stages of each 
formulation or among the formulations was found by the model-based data analysis. This 
observation was likely the result of several contributing factors: a) the primary drug particle 




properties, foremost the nanoparticle size, was the same in all tested formulations and therefore 
the same factor governed the dissolution rate; b) the chosen additives had good solubility in given 
medium; c) further processing by spray drying could had led to amorphisation of part of the 
material and thus could had accelerated the dissolution. 
Further on within the work, the NGI impactor system was adapted to allow deposition of the 
aerodynamically classified powders on a surfactant layer of alveolar A549 cells. Such in vitro 
setup has been used for the first time ever and allowed to mimic the dissolution conditions much 
closer than the modified USP2 setup used previously within the work. This new setup allowed 
deposition of very small powder quantities, which varied based on the tested formulation and the 
deposition stage, on the cell surface. Further on, the appearance of the drug in the basal medium 
was monitored over time. Kinetic analysis was performed to evaluate the kinetics of drug uptake 
into the cells, metabolism into its oleate metabolite, and release into the basal solution. This 
method made it possible to assess the dissolution kinetics of particles in a lung surfactant, thus 
closely mimicking the in vivo fluid composition. Compared to tests in the modified USP2, this 
method was able to discriminate between the different formulations and stages. Differences 
among the formulations’ dissolution kinetics were observed likely due to notably smaller 
dissolution medium amount, which further emphasised the need for a representative study setup 
when developing an in vitro system for example within the attempts of pulmonary in vitro-in vivo 
correlation establishment. Further, this experimental model enabled quantification of the drug 
distribution among the different cell compartments and to assess the extent of drug conjugation 
with oleic acid. It also clearly showed that the dissolution kinetics can be influenced by the 
saturation of the surface lining fluid when large powder amounts deposit on a cell surface, which 
could have potential negative impact on local bioavailability. Possibility to mimic the dissolution-
rate limitation in a representative setup would be very valuable especially for very poorly water-
soluble drugs. 
It is hopefully not too bold to claim that the proposed combination of processes would have the 
potential to become even in an industrial setting a platform technology for processing of any 
poorly water-soluble drug for creation of pharmaceutical powders. For inhalation powders, such 
formulation approach would have clear advantages thanks to the improved aerodynamic 
performance, high and/or multiple drug load possibility. For majority of the drugs, it would 
possibly bring an even faster onset of action thanks to the very fast drug dissolution and it could 
shorten the half time of the very poorly water-soluble drugs such as fluticasone propionate. All 
these would potentially lead to cost savings due to increase of drug amount that reaches the 
patient’s lungs. Also better compliance could be achieved if the improved delivery would for 
example lead to need of reduced dosing regimen. Further, the hereby used processes of wet media 
milling and spray drying are already well established on their own in the pharmaceutical industry 
and both are readily scalable. Moreover, within the frame of this work, solely water was used as 
a solvent, reducing any concerns due to residual solvents content in the resulting powder. 
However, spray drying is known to be an expensive pharmaceutical process and the yield of wet 
media milling is often suboptimal due to product retention in the milling media. Unless the 
processes would be further optimized, it might be questionable whether the formulation benefits, 
which such technological combination could bring, would outweigh the higher price tag that 
would inevitably come along with it compared to the conventional processes. It is possible that 
for the traditional, locally acting drugs such as corticosteroids, it would not be justifiable to use 
such complex and pricey process chain. Yet, the need to deliver systemically acting drugs to the 




alveolar region would ask for use of either very small-sized or engineered particles. As very small 
micronized particles would likely show poor aerodynamic performance, it can be assumed that 
engineered particles with their numerous beneficial psychical-chemical properties would offer 
considerably more reliable delivery option. Engineered particles could also provide a way 
forward for drugs that cannot be micronized and thus processed in the conventional manner. 
Furthermore, spray drying alone is becoming a very attractive process for formulation of 
biological molecules intended for pulmonary delivery, as done for example within the PulmoSol® 
technology [110]. Thanks to spray drying, the otherwise solution-based biological drug substance 
can be formulated into a powder, which generally provides better stability over a liquid 
formulation. For such expensive drug substances, which biomolecules undoubtedly are, using a 
more complex and expensive process that however provides superior product performance and 
stability is possibly justifiable. Given the rise in biotechnology and its products, alongside with an 
increasing interest for development of patient-centric products, it can be expected that the spray 
drying technology will find its place among the key pharmaceutical processes. And for such cases, 
the possibility to characterize and understand on a deeper level the spray dried product 
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7.1 List of abbreviations 
ADME Absorption, Distribution, Metabolism, Excretion  
ALI Air-Liquid Interface  
ALICE Air-Liquid Interface Cell Exposure  
API Active Pharmaceutical Ingredient 
APSD Aerodynamic Particle Size Distribution  
COPD Chronic Obstructive Pulmonary Disease  
CULTEX LTC-C Computer-Controlled Long-Term Cultivation  
DPI Dry Powder Inhaler 
DPPC Dipalmitoylphopshatidylcholine  
FPF Fine Particle Fraction  
FPM Fine Particle Mass  
hAEpC human Alveolar Epithelial Cells 
ICH 
International Council for Harmonisation of Technical Requirements 
for Pharmaceuticals for Human Use 
IVIVC in vitro-in vivo correlation  
LPP Large Porous Particle 
NGI Next Generation Impactor 
NP Drug nanoparticle 
PADDOCC Pharmaceutical Aerosol Deposition Device on Cell Culture  
pDMI Pressurised Metered Dose Inhalers 
TEER Transepithelial Electrical Resistance  
TPGS D-α-Tocopherol Polyethylene Glycol 1000 Succinate 
USP United States Pharmacopeia 






7.2 List of symbols 
γ interfacial tension at the particle surface 
η dynamic viscosity 
κ evaporation rate 
λ mean free path of a gas 
ρP particle density 
ρ0 unit density 
χ shape factor 
ω stirrer angular velocity 
  
C dissolved drug  concentration  
CC Cunningham correction factor  
C∞ solubilities of a particle of infinite size 
Cr solubilities of a particle of radius r 
Cs drug  saturation solubility 
d particle diameter 
dA aerodynamic diameter 
dE equivalent volume diameter 
Df, D diffusion coefficient 
Di diffusion coefficient of the solutes in the droplet 
Dj jet diameter  
Em,P specific energy input 
FD drag force 
FG gravitational force 
g gravitational acceleration 
h thickness of diffusion boundary layer 
kB Boltzmann's constant 
m dissolved drug amount 
M molecular weight of the solute 
M(t) torque measured during milling 
M0 no-load torque 
mp product mass 
Pe Péclet number 
r radius 
Re Reynolds number 
S surface area 
Stk Stokes number 
t time 
T absolute temperature 
U nozzle exit velocity  
V particle velocity  






8.1 Production of fast-dissolving low-density powders for 
improved lung deposition by spray drying of a 
nanosuspension 
Below are shown dissolution tests of the investigated formulations. Stars represent the dissolved 
drug concentration in the bulk solution (Cb), whereas lines represent fitted dissolution profile 












































































































8.1.3 X-ray powder diffraction 
Below are shown XRPD diffractograms of budesonide raw material, budesonide nanosuspension 
(WMM NS), and spray-dried nanosuspension without any matrix former (NS/-). 
 
